Rare anterior uveitis entities by Garip-Kuebler, Aylin
 Aus der Augenklinik der Ludwig-Maximilians-Universität München 
Direktor: Prof. Dr. Anselm Kampik 
 
 
 
Rare Anterior Uveitis Entities 
 
 
Dissertation zum Erwerb des Doktorgrades der Medizin  
an der Medizinischen Fakultät  
der Ludwig-Maximilians-Universität München 
 
 
 
 
 
 
 
vorgelegt von 
 
 
Aylin Garip-Kübler 
           aus Cerkezköy 
           München 2014 
 
 
 
 
 
	   
 
 
   
 
 
  Gedruckt mit Genehmigung der Medizinischen Fakultät 
    
   der Ludwig-Maximilians-Universität München 
 
 
 
 
 
 
 
 
 
 
  Berichterstatter:   Prof. Dr. Gerhild Wildner 
 
 
 
 
  Mitberichterstatter:  Priv. Doz. Dr. Ulrich Schaller 
 
 
 
  Mitbetreuung durch den 
  promovierten Mitarbeiter: Prof. Dr. med. Stephan R. Thurau 
 
 
 
 
  Dekan:    Prof. Dr.med. Dr. h.c. Maximilian Reiser, FACR, FRCR 
 
 
 
 
  Tag der mündlichen Prüfung: 23.1.2014 
 
 
 
 
 
 
 
 
 
 
 
 
 
	1. Table of contents 
 
1.  Table of contents.......................................................................................................................1 
2.  List of abbreviations..................................................................................................................2 
3.  Introduction................................................................................................................................3 
3.1 Etiology.......................................................................................................................................3 
3.1.1. Differentiation of uveitis by the localization of inflammation................................................3 
 Posterior vs. anterior uveitis.........................................................................................................3 
3.1.2. Differentiation of uveitis by the type of inflammation............................................................4  
 Granulomatous vs. non-granulomatous.......................................................................................4 
3.1.2.1. Granulomatous anterior uveitis................................................................................................7 
 Sarcoidosis...................................................................................................................................7 
3.1.2.2. Non- granulomatous anterior uveitis.....................................................................................10 
 HLA-B27 associated anterior uveitis..........................................................................................10 
3.1.3. Differentiation of uveitis by the cause of inflammation.......................................................12 
 Infectious vs. autoimmune disease............................................................................................12 
 Immune characteristics of the eye.............................................................................................12 
3.1.3.1. Infectious uveitis......................................................................................................................14 
3.1.3.1.1. Bacteria..................................................................................................................................14 
 Tuberculosis...............................................................................................................................14 
3.1.3.1.2. Viruses...................................................................................................................................17 
 Herpes viruses...........................................................................................................................17 
 Fuchs: Rubella...........................................................................................................................17 
3.1.3.1.3. Parasites................................................................................................................................18 
 Toxoplasma gondii.....................................................................................................................18 
3.1.3.2. Autoimmune uveitis.................................................................................................................19 
 Sympathetic ophthalmia.............................................................................................................19 
3.1.3.3. „Idiopathic“ uveitis..................................................................................................................19 
4. Results: Publications..............................................................................................................19 
 Uveitis in a patient treated with Bacille-Calmette-Guérin: Possible Antigenic Mimicry of 
 Mycobacterial and retinal Antigens............................................................................................20 
 Bilateral Acute Iris Transillumination..........................................................................................28 
5. Discussion................................................................................................................................36 
5.1. Uveitis in a patient treated with Bacille-Calmette-Guérin: Possible Antigenic Mimicry of 
 Mycobacterial and retinal Antigen..........................................................................................36 
5.2. Bilateral Acute Iris Transillumination.....................................................................................39 
6. Summary...................................................................................................................................44 
7.  Zusammenfassung..................................................................................................................45 
8. References................................................................................................................................46 
9. Acknowledgement……………………………………………………………………………………52 
1
	2. List of Abbreviations: 
 
α-MSH:   α-melanocyte-stimulating hormone 
AAU:  Acute anterior uveitis 
AC:  Anterior chamber  
ACAID:  Anterior-chamber-associated immune deviation 
ACE:  Angiotensin converting enzyme  
APC:  Antigen presenting cells  
APMPPE: Acute posterior multifocal placoid pigment epitheliopathy 
AS:  Ankylosing spondylitis  
AU:  Anterior uveitis 
BADI:  Acute depigmentation of the iris 
BAIT:  Bilateral acute iris transillumination  
BCG:  Bacille-Calmette-Guérin 
BHL:  Bilateral hilar lymphadenopathy  
BRB:  Blood-retina-barrier  
CMV:  Cytomegalovirus 
EAU:  Experimental Autoimmune Uveitis  
EBV:  Epstein-Barr virus 
FUS:  Fuchs uveitis syndrome 
HLA:  Human leucocyte antigen 
HSV:  Herpes simplex virus 
IFN-γ:  Interferon-gamma  
IL:  Interleukin 
KP:  Keratic precipitates 
PAS:  Peripheral anterior synechiae 
PDS:  Pigment dispersion syndrome 
PPD:  Purified protein derivative 
RPE:  Retina pigment epithelium 
Rpf:  Resuscitation promoting factors  
sIL-2R : Soluble interleukin-2 receptor  
SO:  Sympathetic ophthalmia 
SpA:  Spondyloarthropathy  
Tb:  Tuberculosis 
TJ:  Tight junctions  
TLR:  Toll-like receptors  
TM:  Trabecular meshwork  
TNF- α:   Tumor necrosis factor-α 
VZV:  Varicella zoster virus 
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3. Introduction 
Uveitis is defined as the inflammation of any part of intraocular tissue. This includes the uveal tissue 
iris, ciliary body, choroid and neural tissue retina, papilla and retinal pigment epithelium as well as the 
anterior chamber and the vitreous. Depending on the site of the primary inflammation uveitis is 
classified into 4 major groups: anterior, intermediate, posterior and panuveitis (inflammation of the all 
structures) 1.  
 
3.1. Etiology 
3.1.1. Differentiation of uveitis by the localization of inflammation 
Posterior vs. anterior uveitis 
Anterior uveitis is the most common and less destructive form of uveitis and accounts for 49 2 to 92 3 % 
of all uveitis cases in Europe and 76% in Australia 4. It is more common in young adults between the 
ages of 20 to 50, but may also affect children and the elderly people. Anterior uveitis is an inflammation 
of the iris and or the anterior ciliary body of the eye. It is characterized by a breakdown in the blood–
aqueous barrier and acute inflammation of the iris and ciliary body due to an infectious or autoimmune 
cause. This results in leakage of serum proteins and cells into the anterior chamber. On slit lamp 
examination this can be seen as flare or fibrin in the anterior chamber (AC) and cells either floating in 
the AC, sedimenting as hypopyon or clustering as keratic precipitates (KP) on the corneal endothelium 
forming granuloma-like structures. Small nodules (granuloma) can also be seen on the iris named 
Berlin nodules located on the iris base in the AC angle, Busacca nodules on the iris or Koeppe nodules 
on the pupillary margin. Other findings are ciliary congestion of the conjunctiva (perilimbal injection) 
and anterior or posterior synechia.  
 
Intermediate uveitis is defined as an inflammation predominantly involving the pars plana, the 
peripheral retina and the vitreous.  
 
Posterior uveitis involves the inflammation of the retina (retinitis), choroidea (choroiditis), and/or 
arteries and veins (vasculitis). Retinitis may be focal, multifocal, geographic or diffuse. Active lesions 
are characterized by whitish retinal opacities with indistinct borders due to the surrounding oedema. 
Choroiditis may also be focal, multifocal, geographic or diffuse. A round, yellow nodule in the choroidea 
is a typical finding of choroiditis. Vasculitis may occur as a primary condition or as a secondary finding 
3
	adjacent to a focus of retinitis. Active vasculitis is characterized by yellowish or grey-white, patchy, 
perivascular cuffing, which may be associated with haemorrhage. 
 
Panuveitis is the inflammation, which involves the entire uveal tract without a predominant site.  
 
3.1.2. Differentiation of uveitis by the type of inflammation 
Granulomatous vs. non-granulomatous 
Depending on the clinical findings the type of inflammation seen in AU can be classified into 2 groups: 
granulomatous and non-granulomatous AU. Frequently other clinical features like type of onset, 
formation of synechia or secondary iris atrophy are associated with these groups and will be helpful in 
differentiating these disorders (Tab. 1). 
 
Tab. 1: Clinical features of uveitis associated with granulomatous and non-granulomatous uveitis 
 Non-granulamatous 
 
Granulamatous 
Onset 
 
Acute, recurrent Slower onset, chronic 
Keratic precipitates (KP) 
 
Dusty Mutton-fat KP’s 
Anterior chamber (AC) Flare, isolated cells, fibrin, 
± hypopyon 
Less flare, cells 
Posterior synechia 
 
+ - 
Iris nodules - +  
Iris atrophy  - + 
 
4
	Anterior Granulomatous Uveitis 
 
1. Infectious: (uni-/ bilateral) 
 Viral AU (often unilateral) 
 Herpes simplex virus (HSV) 
 Varizella zoster virus (VZV) 
 Cytomegalovirus (CMV) 
 Epstein-Barr Virus (EBV) 
 Fuchs’ Uveitis (mostly chronic rubella virus) 
 Posner-Schlossman syndrome (CMV?) 
 
 Bacterial AU  
 Tuberculosis 
 Syphilis 
 Leprosy  
 
2. Autoimmune (often bilateral) 
 Sarcoidosis 
 Vogt-Koyanagi-Harada’s Disease (VKH) 
 Sympathetic ophthalmia 
 Lens-induced uveitis 
 
Non-granulomatous Uveitis: 
 
1. HLA-B27 associated anterior Uveitis (AU) 
a. Ocular involvement only (no association with systemic disease) 
b.   Associated with systemic disease 
 Axial spondyloarthropathy (SpA) 
 Reactive arthritis 
 Psoriatic arthropathy 
 Inflammatory bowel disease 
 Undifferentiated spondyloarthropathies 
 Juvenile idiopathic artritis (JIA) 
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2. Idiopathic acute anterior uveitis 
3. Behçet’ s disease 
4. Tubulointerstitial nephritis and uveitis syndrome (TINU) 
5. Kawasaki disease 
6. Medication-induced uveitis 
7. Traumatic uveitis 
8. Infectious causes 
 Leptospirosis 
 Rickettsioses 
 Poststreptococcal syndrome uveitis 
 Bacterial endophthalmitis 
 
       Taken and modified from Gupta et al. 2009: 31 5  
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	3.1.2.1. Granulomatous anterior uveitis 
Granulomatous anterior uveitis is characterized by mutton-fat keratic precipitates (Fig. 1), which are 
composed of macrophages or giant cells and additional T- and B-cells. Another typical finding is 
nodules consisting of inflammatory cells, which can be identified on the pupillary margin (Koeppe 
nodules: Fig. 2), on the iris (Busacca nodules: Fig. 2) and the iris base in the AC angel (Berlin 
nodules). Also like in non-granulomatous AU, cells floating in AC and flare can be seen.  
 
 
Fig. 1: Mutton fat keratic precipitates (KP’s) on the 
endothelium of the cornea 
Fig. 2: Busacca (black arrow) and Koeppe (red arrow) nodules 
of the iris 
                    (Figures taken from Herbort et. al.8) 
 
Sarcoidosis 
Sarcoidosis is a chronic granulomatous multisystem disease of unknown aetiology. Clinical 
presentation of the disease varies widely from asymptomatic to severe cases. The disease affects 
predominantly lungs and the thoracic lymph nodes. Other frequently affected organs are eyes and skin. 
The most common skin lesions are erythema nodosum and sarcoid granulomas.  Ocular involvement is 
seen in 25%–60% of patients with systemic sarcoidosis 6. The most common ocular manifestations are 
with 30% to 70% uveitis and with 40% conjunctival nodules 6- 7. 
 
Clinical manifestations of ocular sarcoidosis: 
Uveitis:  
Systemic involvement is frequently missing in patients with ocular sarcoidosis. Recently an 
international workshop has defined criteria for the diagnosis of ocular sarcoidosis. 
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	Results of the First International Workshop on Ocular Sarcoidosis (IWOS) 8 
I. Clinical signs suggestive for sarcoidosis 8 
1. Mutton-fat KPs (large and small) and/or iris nodules at pupillary margin (Koeppe) or in stroma 
(Bussacca) 
2. Trabecular meshwork (TM) nodules and/or tent-shaped peripheral anterior synechiae (PAS) 
3. Snowballs/ string of pearls vitreous opacities 
4. Multiple chorioretinal peripheral lesions (active & atrophic) 
5. Nodular and/ or segmental peri-phlebitis (candlewax drippings) and/ or macroaneurism in an 
inflamed eye 
6. Optic disc nodule(s)/ granuloma(s) and/ or solitary choroidal nodule 
7. Bilaterality (assessed by clinical examination or investigational tests showing subclinical 
inflammation) 
 
II. Laboratory investigations or investigational procedures 8 
1. Negative tuberculin test in a BCG vaccinated patient or having had a  positive PPD (or Mantoux) skin 
test previously 
2. Elevated serum angiotensin converting enzyme (ACE) and/ or elevated serum lysozyme 
3. Chest x-ray; look for bilateral hilar lymphadenopathy (BHL) 
4. Abnormal liver enzyme tests  
5. Chest CT-scan in patients with negative chest x-ray 
 
In 1989 Rothova et al.9 have reviewed retrospectively 121 patients with biopsy proven sarcoidosis and 
41% had an associated ocular disease. The most frequently seen ocular involvement was uveitis (28% 
anterior uveitis, 30% posterior and panuveitis). It is important to consider sarcoidosis in cases with 
granulomatous AU because in this study uveitis was in 86% an early feature before the diagnosis of 
sarcoidosis 9 and lung involvement is relatively rare in patients with ocular sarcoidosis. 
 
In spite of having these diagnostic criteria, the diagnosis of sarcoidosis remains challenging. 
Angiotensin-converting enzyme (ACE), which is a supportive criterion in the diagnosis, is produced in 
pulmonary macrophages of the sarcoid granuloma and vascular endothelium. The serum ACE shows 
the total body granuloma burden in sarcoidosis 10 and serum ACE is elevated in 60-90% of patients 
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	with active sarcoidosis 11. However there are other conditions like disseminated tuberculosis, fungal 
infections, hyperthyroidism, and Gaucher disease, which can also be associated with elevated ACE 
levels. In children ACE is frequently elevated for unspecific reasons. Therefore this test remains only 
fairly specific for the diagnosis of sarcoidosis 12.  
 
Another surrogate marker for sarcoidosis is the soluble interleukin-2 receptor (sIL-2R). In 1990 Keicho 
et al. have shown that the elevated serum sIL-2R was significantly higher in untreated sarcoidosis 
patients in comparison to the healthy population 13. This study also showed a positive correlation 
between the serum concentration of sIL-2R and serum ACE activity suggesting the use of IL-2R level 
in serum as a surrogate marker for the activity of the disease 13.  
  
9
	 
3.1.2.2. Non-granulomatous anterior uveitis 
Non-granulomatous anterior uveitis is characterized by the lack of adhering cells forming granuloma-
like structures. Typical clinical findings of non-granulomatous AU are cells, flare, and fibrin in the 
anterior chamber as well as dusty precipitates composed primarily of neutrophils and few other 
leucocytes on the posterior corneal surface.  
 
HLA-B27 associated anterior uveitis 
Human leucocyte antigen (HLA) B27 is highly associated with several autoimmune diseases like axial 
spondyloarthropathy (former SpA or ankylosing spondylitis) and anterior uveitis. HLA-B27 associated 
AU is the most common single entity of AU comprising 18 to 32% of AU cases 14, 15, 16. It also has 
distinct clinical features that differentiate it from HLA-B27-negative acute anterior uveitis (AAU). Typical 
presentation of HLA-B27 AAU is sudden onset and limited duration with alternating, unilateral 
recurrence and symptoms of redness, pain, epiphora, photophobia, and blurred vision. 
 
The clinical findings of HLA-B27-associated AU are perilimbal hyperemia, dusty keratic precipitates  
(fig. 3), cells, which can accumulate as hypopyon (fig. 4) and flare in AC. In cases of severe 
inflammation, fibrinous exudation in the AC can be seen. This fibrinous exudation may cause posterior 
synechiae (fig. 5). The duration of the acute episode is quite variable, but usually lasts for 4-6 weeks 17.  
There are many studies about the statistical correlation of HLA-B27 and AU. In one study, 43% of 
patients with acute anterior uveitis had a positive HLA-B27 18.  
 
In 2004 Monnet et al.19 have shown that a HLA-B27-associated extraocular disorder was seen in 
77.7% of the cases, who had an HLA-B27-associated AU. Of these patients, 46.3% had an ankylosing 
spondylitis (AS), 9.7% presumed AS, 12% undifferentiated spondyloarthropathy (SpA), 1.1% psoriatic 
arthritis, 3.4% reactive arthritis, 2.9% Behcet’s disease and 2.3% had inflammatory bowel disease. In 
22.3% no systemic disease was found.  
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Figure 3: Fine, dusty keratic precipitates in HLA-B27 associated non-granulomatous anterior uveitis 
 
 
 
 
 
 
 
 
 
Figure 4: Hypopyon (red arrow) and conjunctival hyperemia due to severe iritis 
 
 
 
 
 
 
 
 
 
 
Figure 5: Posterior synechia (red arrow) after repeated episodes of HLA-B27 associated AAU 
 
The other causes of non-granulomatous AU are Behcet’s disease, tubulointerstitial nephritis and uveitis 
–TINU- Syndrome, Kawasaki’s disease, traumatic uveitis, bacterial endophthalmitis, borrelliosis, 
rickettsioses, and leptospirosis. These are rare uveitis entities and should be ruled out in therapy 
refractive cases.  
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	3.1.3. Differentiation of uveitis by the cause of inflammation 
Infectious vs. autoimmune disease 
Immune characteristics of the eye 
For years the eye has been considered as an immune privileged organ. There are many unique 
characteristics of the eye, like the blood-retinal barriers (BRB), absence of lymphatic drainage and 
special immunosuppressive factors, which contribute to this immune privilege.  
 
The BRB consisting of inner and outer components plays an important role in the immune privilege 20. 
The inner BRB, which is also called the true barrier is formed by tight junctions (TJ) of non-fenestrated 
endothelial cells and surrounded by, astrocytes, Müller cells and pericytes 20, 21. The outer BRB, which 
is also called an immunoregulatory gate, located on the Bruch membrane and outside the subretinal 
space and the outer neural retina, is formed by the tight junctions between cells of the retina pigment 
epithelium (RPE) and fenestrated choriocapillaris 20, 21. The third component of the ocular barrier 
system is the blood-aquous barrier, which is located at the ciliary body 21. Ciliary body produces the 
aqueous humor and this barrier is formed by the tight junctions of non-pigmented ciliary body 
epithelium on the proximal side of the aqueous humor and by the fenestrated endothelial cells on the 
other side 21, 22. 
 
Another known factor is the anterior-chamber-associated immune deviation (ACAID) and 
immunosuppressive mediators like TGF-β or α-melanocyte-stimulating hormone (α-MSH), which 
prevent the invasion of the non-activated leucocytes 21, 23. In this phenomenon the antigens in the 
anterior chamber are captured by antigen presenting cells (APC), which migrate to the spleen, where 
they change natural killer cells, CD4+ and CD8+ T cells into a regulatory phenotype 21. This 
mechanism is considered as a generation of peripheral tolerance to eye antigens using the systemic 
immune system 21.  
 
Another special feature of the eye is the absence of the lymphatic drainage. Like brain, placenta, and 
testes the eye has no direct lymphatic drainage, which also prevents the immune response 24, 25. 
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	Since the initiation of immune responses to ocular antigens in the eye is prevented by those 
mechanisms, an autoimmune response leading to an intraocular inflammation has to be induced 
outside of the eye with antigens imitating ocular autoantigens (“antigenic mimicry”).  
 
According to the expression of CD8 or CD4, there are two types of T-cells. CD8+ T-cells recognize an 
8-10 amino acids long antigen peptide presented by HLA-class-I antigens. These peptides originate 
most commonly from intracellular metabolism, particularly if this metabolism is aimed to replicate 
virions after viral infection. CD8+ T-cells have a crucial role as cytotoxic cells in the elimination of virus-
infected cells or tumor cells but they can also act as regulatory cells.  
 
CD4+ T-cells recognize antigen peptides presented by HLA-class II molecules. These peptides are 
more variable in their length compared to peptides presented by HLA-class I molecules. HLA-class II 
molecules however, often present peptides emanating from lysosomal metabolism. These peptides 
result from phagocytation and following intracellular degradation. To a lower extent it is also possible 
that an exchange of peptides from the extracellular environment is presented on the surface of HLA-
class II antigens. 
 
Experimental autoimmunuveitis (EAU) in Lewis rats is a well-known model for human uveitis 23. In rat 
model it was shown that, S-Ag when injected at a site far from the eye, causes an immune mediated, 
bilateral inflammatory response in the eye 23. Retinal S-Ag is one of the most potent uveitogenic 
antigens 26. This antigen is localized in the photoreceptor region of the retina and in pineal gland in 
some species. In 2005 Wildner et al. have described peptides from rotavirus (Rota) and from bovine 
milk casein (Cas), which could cross-react with retinal S-Antigen, due to the amino acid sequence 
homologies, causing an inflammatory reaction in the eye 27. 
 
In 2008 Wildner et al.23 used a cross-reactive ocular antigen, mimicking ocular proteins in rat model to 
activate the T-cells. The activated T cells can enter the eye by passing the blood-retina barrier and 
then they are reactivated by cross-reactive retinal antigen, which is called antigen mimicry 23. This 
concludes that activated T-cell of any kind can pass the blood-retina barrier and invade the eye without 
causing any tissue damage 23. But if a specific activated T-cell finds its specific or its cross-reactive 
antigen, then it gets reactivated. Those reactivated T-cells can stimulate the inflammatory cells, which 
13
	cause the tissue destruction in the eye 23. As a conclusion, antigenic mimicry can explain extraocular 
activation of a cross-reactive immune response finally targeting ocular antigens. 
 
3.1.3.1 Infectious Uveitis 
3.1.3.1.1 Bacteria 
Tuberculosis 
Tuberculosis (Tb) is another multisystem disease, which predominantly affects the lungs, but can 
involve every organ. With worldwide 8 million new cases approximately and 3 millions deaths per year, 
tuberculosis remains as the world’ s leading infectious cause of death 28, 29. 
 
Tuberculosis is usually classified as pulmonary Tb and extrapulmonary Tb. Extrapulmonary 
tuberculosis can involve lymph nodes (30.9 %), pleura (23%), genitourinary system (11.9 %), bone and 
joint (9.8 %), miliary (7.3 %), meninges (4.6  %), peritoneum (3.3%), and all other forms combined 
(9.8%) 30. 
 
Tuberculosis is an airborne infection caused by Mycobacterium tuberculosis, primarily affecting the 
lungs. In a resistant host, the mycobacteria are usually destroyed by the alveolar macrophages. If the 
alveolar macrophages fail to destroy the mycobacterium, then the bacilli will multiply until the 
macrophage bursts. The bacilli is released from the macrophage and phagocytosed by non-activated 
monocytes/ macrophages or other alveolar macrophages and a relationship begins between the host 
and the bacilli. In this time period bacilli multiplies. 
 
The interaction between the components of mycobacterium and Toll-like receptors (TLR) causes the 
macrophages to produce inflammatory cytokines and chemokines, which serve as a signal of infection 
31, 32. This signal causes the migration of macrophages and resident dendritic cells to the lungs 32. The 
bacteria containing dendritic cells mature and migrate to the regional lymph node 33, 34. In the regional 
lymph node CD4 and CD8 T cells are primed against mycobacterial antigens. Those T cells migrate 
back to the site of infection in the lungs 32. A delayed type of hypersensitivity reaction produced by T 
cells, especially cytotoxic T cells, is responsible for the destruction of those bacilli filled macrophages, 
which causes a formation of granuloma, with a central area of necrosis. But despite of all the efforts of 
the immune system the bacilli are not completely destroyed. The accumulation of T cells and 
14
	macrophages result in the formation of this granuloma. The granuloma of the lungs is a typical finding 
in Tb and consists of macrophages, CD4 and CD8 T cells, dendritic cells, endothelial cells, fibroblasts, 
and B cells 32, 35. However some of those bacilli filled macrophages escape and enter the lymphatic or 
blood system and reach the extrapulmonary organs 36. In about 10% of the affected cases a primary 
infection causes an active disease 37. However the remaining 90% of the infected cases are non-
infectious and symptom-free (latent Tb). The estimated risk of lifetime reactivation is between 2% and 
23% 38. 
 
Reactivation of the disease occurs when the latent bacili from the old granulomatous lesions become 
active 39. The mechanism of reactivation is not known yet. The control of Tb is thought to be mediated 
by interferon-gamma (IFN-γ) producing T-cells 40. Also both CD4 and CD8 T lymphocytes play an 
important role in controlling the growth of M. tuberculosis 40. The reactivation takes place when the 
immune response of the host weakens or in cases with suppression of the immune system like in HIV 
positive individuals with low CD4 T-cell counts 39. Flynn and Chan 41 have shown in mice that in the 
immune response associated with the latent phase, CD8+ T-cells play a more significant role in 
comparison to the primary infection of Tb where CD4+ cells are more important.  
 
Recently there have been many publications speculating the importance of group of proteins, called 
resuscitation promoting factors (rpf) in the reactivation of the disease 42. M. Tuberculosis has 5 rpf 
proteins, which are coded by rpf genes 42. It is believed that in case of an environmental stress, the 
bacteria causes a thickening and decreased permeability of the cell wall by heavy cross-linking 
between peptidogylcan strands 42. When the stress is removed, rpf genes are activated resulting the 
production of rpf proteins, which snip the tight peptidogylcan strands and the growth phase of the 
bacteria restarts 42. However the real pathophysiology of the reactivations remains still mysterious. 
 
Ocular involvement in tuberculosis is thought to be rare, however some publications show the opposite. 
Bouza et al. have shown in 1997 that 18 of 100 patients with proven systemic tuberculosis had an 
ocular involvement 43. Clinical manifestations of ocular tuberculosis are anterior, intermediate and 
posterior uveitis. All types of ocular tuberculosis are characterized by granulomatous inflammation.  
 
The anterior uveitis seen in tuberculosis has usually a chronic course with typical signs of 
15
	granulomatous uveitis. Moderate to severe vitritis in ocular Tb can be isolated or in association with 
chorioretinitis. 
 
Posterior uveitis is the most common form of ocular tuberculosis. According to Bouza et al. 17 out of 18 
patients with ocular involvement of tuberculosis had chorioditis 43. A choroidal granuloma localized 
deep in the choroid is a hallmark of the disease. Those granulomas have a yellow to white appearance, 
are usually few in number and located at the posterior pole. In this study the other associated lesions 
were papillitis, retinitis, and vasculitis 43.  
 
Because of the difficulties in the diagnosis of the ocular Tb, this ocular disease can be overlooked or 
misdiagnosed. Recently there have been publications about the promising results in the diagnosis of 
tuberculosis with PCR from the aqueous samples. The first publication was in 1994 by Kotake et al.44, 
who detected M. tuberculosis by PCR in aqueous samples in 2 patients with active retinal vasculitis. 
Then in 1999 Arora et al.45 have shown in 53 aqueous samples of patients with granulomateous uveitis 
(including one or more of the following: 1. active vasculitis, 2. anterior vitreous cells, 3. snowball 
opacities, 4. snowbanks in the pars plana, 5.retinochoroiditis), 20 patients had a positive PCR for M. 
tuberculosis. In the same study the patients having a positive PCR were treated with anti-tuberculosis 
treatment and 4 months after the treatment PCR from the aqueous samples were repeated and was 
negative. Those patients also have shown a clinical improvement of the disease after the Tb-treatment. 
The proven DNA of M. tuberculosis indicates an invasion of the bacteria in the eye. The question is: 
Can the ocular tuberculosis be ruled out after not finding any DNA in the aqueous samples, but having 
typical clinical features of ocular tuberculosis? More recently developed molecular techniques like 
PCR, which detects the M. tuberculosis using DNA probes are promising. However the negative 
samples can be negative due to a low number of organisms in small samples of ocular fluids 45. The 
other theory in the ocular involvement is the antigen mimicry, which can explain the negative PCR for 
M. tuberculosis in spite of having the typical clinical features 46. According to this theory in addition to 
our classical knowledge of infectious organisms in the eye, uveitis can also be caused as a result of 
immune stimulation due to possible antigen mimicry.  
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	3.1.3.1.2. Viruses 
Herpes viruses 
Human herpes virus infections are one of the major causes of morbidity worldwide. Six members of the 
herpes virus family are responsible for herpetic eye disease: HSV 1, HSV 2, VZV, EBV, CMV, and 
human herpes virus 8 47. 
 
Herpetic eye disease can involve almost all parts of the eye. Clinical presentation includes blepharitis, 
conjunctivitis, scleratis, keratitis, anterior uveitis, acute retina necrosis, choroiditis, and optic neuritis. 
The diagnosis of herpetic AU is based on clinical features. Clues leading to the diagnosis of herpetic 
AU, are mutton-fat keratic precipitates (especially in the inferior 1/3 of the corneal endothelium), 
reduced corneal sensitivity in comparison to the other eye, localized corneal scar or oedema, cells and 
flare in the AC, focal areas of iris atrophy (transillumination of the iris), and a distorted pupil.  
 
The patients often complain about blurred vision, pain, and photophobia. Herpetic AU is usually 
unilateral and frequently seen with keratitis. However it can also occur without corneal involvement 47. 
The treatment of herpetic AU is based on antiviral agents (aciclovir, valaciclovir, and famciclovir). Most 
of the herpetic AU patients also require topical corticosteroids and/ or mydriasis for the treatment of the 
AU.  
 
Fuchs: Rubella 
Fuchs’ uveitis syndrome is another syndrome, which causes the depigmentation of the iris. Typical 
clinical findings are unilaterality, generalized, fine, stellate keratic precipitates, iris atrophy, low-grade 
anterior uveitis and vitritis 48. Other features are iris nodules (more then 30% of the cases) and the 
smoothening of the stroma at the early stage of the disease. 5-10% of the cases are bilateral. It is 
mostly asymptomatic and the most common complications are subcapsular cataract and glaucoma. A 
chronic rubella infection or CMV infection is assumed to be the cause of Fuchs’ uveitis syndrome 49, 50.  
 
In 1997 Muhaya et al. have shown the predominantly elevated levels of CD8+ T-cells in the anterior 
chamber taps of the patients with Fuchs’ uveitis 51. It can be speculated that the cause of the typical iris 
transillumination is the direct cytopathic effect of the virus on the infected tissue. 
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	3.1.3.1.3. Parasites 
Toxoplasma gondii 
Toxoplasma gondii infection is an important cause of chorioretinitis worldwide. The characteristic lesion 
is a focal necrotizing retinitis that initially appears as a yellowish-white, elevated cotton patch with 
indistinct margins, usually located in the posterior pole adjacent to pigmented scars. The diagnosis of 
toxoplasmic retinitis is based on clinical features. In atypical presentations, or when the fundus is 
hidden by vitreal inflammation, aqueous humor analysis could be used as a diagnostic tool.  
 
Figueroa et al. 52 have shown that the detection of T. gondii genoma in aqueous humor by PCR is an 
effective diagnostic tool. However a negative result does not rule out a possible ocular toxoplasmosis52. 
The proven DNA of T. gondii indicates an invasion of the parasite in the eye. This could explain that, 
like in herpes uveitis, the persistence of the agent in the eye can cause the activation of the 
inflammation. 
 
There are probably many more proteins, e.g. from infectious agents, that might be cross-reactive with 
ocular autoantigens. In the following, we discuss a rare side effect of the therapeutic use of Bacille 
Calmette Guérin (BCG) for bladder carcinomas. We described a case of potential antigenic mimicry of 
proteins from BCG and Mycobacterium tuberculosis with several retinal autoantigens, providing a 
further link between (extraocular) infections and intraocular autoimmunity 46. 
 
On the other hand, Fuchs uveitis, which has been regarded as „autoimmune“ for a long time, was 
finally identified to be a chronic infection with rubella or herpes viruses/CMV 49, 53. In these cases, a 
chronic trigger of the virus-specific T cell response leads to chronic intraocular inflammation and 
granuloma formation.  
 
While most herpes viruses cause granulomatous anterior uveitis, varizella zoster virus (VZV) induces 
iris transillumination, which is a cytopathic effect of the virus itself and not caused by a destructive 
immune reaction. In addition to VZV there might be more viruses able to induce lysis of the iris pigment 
epithelium that results in iris transillumination, which, however, have not yet been identified 54. 
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3.1.3.2. Autoimmune Uveitis 
Sympathetic Ophthalmia  
Sympathetic ophthalmia (SO) is an uncommon bilateral granulomatous panuveitis following uveal 
trauma to one eye. This trauma causes a break down in blood-retina-barrier (BRB) resulting a local 
activation of the immune system on one or both eyes. 
 
3.1.3.3. „Idiopathic“ Uveitis 
Autoimmune reaction without preceding infection or trauma should not be possible due to:  
a) blood-retina barrier (BRB) is sequestering the ocular autoantigens from the immune system. Most of 
them only expressed in the eye and not in peripheral tissues. Moreover, BRB can only be passed by 
already activate leukocytes, which cannot be activated to retinal antigens, because they are not 
available outside of the eye.  
b) immune privilege of the eye: induces regulatory T cells/immune tolerance to intraocular antigens 
(example: ACAID). 
c) immunosuppressive factors in the aqueous/vitreous prevent activation of potentially autoaggressive 
effector cells and help inducing regulatory T cells, respectively. 
 
4. Results: Publications 
Both manuscripts are about rare uveitis entities. In the first publication the antigenic mimicry was 
considered as the cause of the uveitis in a patient with bilateral uveitis after the intravesical application 
of Bacille-Calmette-Guérin (BCG) for her bladder carcinoma.  The second manuscript involves a case 
series of 26 patients with new described uveitis entity. In this case series the patients present with 
similar ocular findings of bilateral acute iris transillumination, pigment dispersion, and sphincter 
paralysis. There are two possible explanations for the destruction of the iris pigment epithelium 
resulting in transillumination. The first theory involves the direct cytopathic effect of a virus on the 
infected iris tissue. The second theory is the potential antigenic mimicry of (unknown) viral proteins/ 
peptides of an extraocular (systemic) virus infection and proteins of the iris pigment epithelium, 
recognized by cross-reactive CD8+ cytotoxic T-cells, which destroy the pigmented cells of the iris. 
 
I have contributed to the first manuscript as a first author and the second manuscript as a co-author. In 
the first manuscript I was actively involved in processes concerning literature review, performing 
observations, collecting data, and writing. In the second manuscript I was involved in all processes 
concerning literature review, establishing material and methods, performing observations, collecting 
data, statistical analysis using SPSS, and writing.  
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Uveitis in a Patient Treated with
Bacille-Calmette-Guérin
Possible Antigenic Mimicry of Mycobacterial and
Retinal Antigens
Aylin Garip, MD,1 Maria Diedrichs-Möhring, PhD,1 Stephan R. Thurau, MD,1 Cornelia A. Deeg, VMD,2
Gerhild Wildner, PhD1
Purpose: To investigate the cellular immune response in uveitis developing after intravesical Bacille-
Calmette-Guérin (BCG) applications.
Design: Experimental study.
Participants: A 72-year-old HLA-B27–negative patient with bilateral granulomatous anterior uveitis that devel-
oped during the third cycle of intravesical BCG applications she was receiving for treatment of bladder carcinoma.
Methods: The patient’s peripheral T cell reactivity to ocular autoantigens was compared with the response
to purified protein derivative (PPD) from Mycobacterium tuberculosis. T-cell proliferation and cytokine and
chemokine secretion were measured in vitro.
Main Outcome Measures: Anterior uveitis was treated successfully with topical corticosteroids and
cycloplegics.
Results: The following were demonstrated: proliferation to PPD, interphotoreceptor retinoid-binding protein
(IRBP), and IRBP-peptide R16, as well as secretion of proinflammatory cytokines in response to PPD, retinal
soluble antigen (S-Ag), IRBP, cellular retinal-binding protein (CRALBP), and some S-Ag and IRBP peptides.
Conclusions: These data indicate the generation of a polyclonal autoimmune reaction elicited by BCG.
Amino acid sequence alignments revealed homologies between proteins from M. tuberculosis, BCG, and retinal
antigens, suggesting antigenic mimicry as a potential cause of uveitis in this patient.
Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed
in this article. Ophthalmology 2009;116:2457–2462 © 2009 by the American Academy of Ophthalmology.Uveitis can be caused by intraocular infections or as a result
of immune stimulation. Infections with Mycobacterium tu-
berculosis can cause uveitis when mycobacteria invade the
eye and elicit local granulomatous inflammation.1 M. tuber-
culosis induces a strong T-helper 1 response, which is the
most frequent type of immune response associated with
uveitis. Thus, Freund’s adjuvant, containing lyophilized M.
tuberculosis, together with a retinal autoantigen is used for
inducing experimental autoimmune uveitis in rats and
mice.2 The strong adjuvant effect of M. tuberculosis also is
used therapeutically in humans with bladder carcinomas.
Local instillations of live Bacille-Calmette-Guérin (BCG), a
nonpathogenic strain of Mycobacterium bovis previously
used for vaccine preparation, induces an immune activation
that can be effective in the treatment of the tumor.3 How-
ever, in some cases, undesired side effects, including fever,
prostatitis, hepatitis, pneumonitis, arthritis, sepsis, and uve-
itis, have been observed.4 So far, only a few clinical cases
of uveitis have been reported, and there were no investiga-
tions of the underlying immune response.5–13 In the case of
© 2009 by the American Academy of Ophthalmology
Published by Elsevier Inc.intravesical therapy, BCG usually will not cause infection of
human tissues (other than bladder tumor cells).14 Therefore,
infection of the eye and local granuloma formation to en-
capsulate the mycobacteria is unlikely to be the cause of the
observed uveitis.
Herein, the case of a female patient who underwent BCG
therapy for the treatment of bladder carcinoma is described.
The patient received 3 cycles of BCG over a period of 3
years. During the third cycle, cystitis developed, and sub-
sequently the patient sought treatment for blurred vision. A
granulomatous anterior uveitis, which was controlled easily
with topical corticosteroid therapy after excluding infec-
tious disease, was diagnosed. The patient’s peripheral lym-
phocytes were tested for in vitro responses (T-cell prolifer-
ation and cytokine and chemokine secretion) to tuberculin
(purified protein derivative [PPD]), retinal, and control an-
tigens, and high responses to retinal autoantigens were
detected. Database searches revealed several amino acid
sequence homologies between proteins from BCG and the
retinal autoantigens, suggesting that the observed intraocu-
2457ISSN 0161-6420/09/$–see front matter
doi:10.1016/j.ophtha.2009.05.021
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Ophthalmology Volume 116, Number 12, December 2009lar inflammatory immune response may be the result of
antigenic mimicry, when T cells mistake retinal proteins for
antigens from BCG.
Case Report
A 72-year-old woman was referred by an ophthalmologist to the
authors’ outpatient department with a bilateral granulomatous an-
terior uveitis, which had been ongoing for 3 to 4 days. The patient
reported painless blurred vision, initially in her left eye. Otherwise,
there was no history of previous uveitis. Findings were recorded
according to the Standardization of Uveitis Nomenclature criteria.
Initially, best-corrected visual acuity was 0.8 in the right eye and
0.6 in the left eye. Both eyes showed endothelial granulomatous
precipitates in Arlt’s triangle and 2 cells in the anterior chamber
(Fig 1). There was 1 flare in the right eye and some fibrin on the
temporal part of the iris. Remnants of preexisting posterior syn-
echia were seen on both lenses. The right eye showed Koeppe
nodules. The vitreous in both eyes had some cells and 0.5 haze.
There were no signs of posterior uveitis.
Her medical history revealed ongoing treatment for arterial
hypertension and hypercholesterinemia. Three years earlier, she
was diagnosed with a high-grade noninvasive papillar urothelial
carcinoma (pTaG3). Treatment included transurethral resection,
photodynamic therapy with the photosensitizer 5-aminolaevulinic
acid, and intravesicular instillations of BCG. One year later, the
tumor reoccurred and she was treated again with transurethral resec-
tion and intravesical BCG instillations, without tuberculosis prophy-
laxis. The patient had received neither further chemotherapy nor
corticosteroids. At the time of the first ocular symptoms, she was
tumor free and had received 3 complete courses of 6 BCG instillations
Figure 1. Clinical photographs of patient eyes showing: (A) right eye and
deposits on the lens, and (D) right eye with a normal fundus.each, the last one 7 days before onset of blurred vision.
2458The results of the medical examination were negative with the
exception of the known disorders. She had no rheumatologic
diseases and no history of tuberculosis. A chest radiograph showed
a granuloma of 5 mm in diameter (Fig 2) that had first been
observed in 2002 (3 years before diagnosis of the bladder carci-
noma) and had remained unchanged since then. The radiologist
regarded the location of the granuloma in the lower left field as
atypical for tuberculosis or sarcoidosis and concluded that it was
likely a remnant of pneumonia. The Tine test (intracutaneous prick
test) that was performed after diagnosis of uveitis demonstrated
negative results, despite prior BCG treatment, and she was not
tested before onset of BCG therapy. A tuberculosis quantiferon
gold test was not carried out.
Blood chemistry results were unremarkable. She was negative
for HLA-B27 and positive for HLA-B8 and HLA-B38, and the
ACE level was within normal limits. Serologic analysis for toxo-
plasmosis, Lyme borreliosis, and syphilis demonstrated negative
results. She had low immunoglobulin G and negative immuno-
globulin M titers for herpes simplex virus, varicella zoster virus,
and cytomegalovirus. Polymerase chain reaction analysis of an
anterior chamber tap showed negative results for herpes simplex
virus, varicella zoster virus, and toxoplasmosis. Anterior uveitis
was treated successfully with topical steroids and mydriatics and
the intraocular inflammation had subsided completely 4 weeks
later, when the in vitro cultures with peripheral blood lymphocytes
were initiated.
Materials and Methods
Peptides and Protein Antigens
Retinal soluble antigen (S-Ag) and interphotoreceptor retinoid-
left eye with mutton fat precipitates, (C) left eye with pigmented cellular(B)binding protein (IRBP) were prepared from bovine eyes as de-
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Recombinant cellular retinal-binding protein (CRALBP) was ob-
tained and purified as described.17 Chicken ovalbumin (OVA) was
obtained from SIGMA (Deisenhofen, Germany), and tuberculin
(PPD) and tetanus toxoid (TT) were gifts from Aventis (Marburg,
Germany). Custom peptides were purchased from Biotrend (Cologne,
Germany) and had the following sequences: S-antigen–derived pep-
tides: SAg 281, LPLLANNRERRGIALD; SAg 286, NNR-
ERRGIALDG; PepM, DTNLASSTIIKEG; PDSAg, FLGELTSSEV-
ATEV. Interphotoreceptor retinoid-binding protein–derived peptides:
PI536, GVYLLTSHRTATAA; PI731, DLYILMSHTSGSAA; PI1137,
KSMVILTSTVTAGTAE; R4T, NLYLTIPTARSVGA; R4/R14,
PTARSVGAADGS; R14, PTARSVGAADGSSWEGVGVVPDV;
PDIRBP, VGAADGSSWEGVGV; R16, ADGSSWEGVGVVPDV.
Sequence homologies of retinal autoantigens with proteins from M.
tuberculosis BCG strain were determined by BLAST sequence sim-
ilarity search of the NCBI Gene bank.
Antigen-Specific Stimulation of Peripheral Blood
Mononuclear Cells
Six weeks after onset of clinical uveitis, peripheral blood was
collected with the patient’s informed consent and prior approval of
the ethics committee of the clinic of the Ludwig-Maximilians
University of Munich. Lymphocytes were separated from heparin-
ized peripheral blood by Ficoll density gradient centrifugation
(PAA, Coelbe, Germany) and then were cultivated for 4 days in
flat-bottom microtiter plates (Renner, Dannstadt, Germany) at a
density of 2.5105/ml in RPMI 1640 medium (PAA) supple-
Figure 2. Chest radiograph showing a lung granuloma of 5 mm in diamete
for tuberculosis.mented with 2 mM L-glutamine, 100 IU penicillin G (PAA), 10mg/ml streptomycin sulfate (PAA), and 1 MEM essential and
nonessential amino acids (PAA). Each culture contained 5% of
heat inactivated pooled human serum. Retinal soluble antigen
(S-Ag), IRBP, CRALBP, chicken ovalbumin, and tetanus toxoid
were used at concentrations of 10 g/ml, PPD was used as indi-
cated, and the peptides were used at concentrations of 20 g/ml.
Chicken ovalbumin as a common nutritional protein and tetanus
toxoid as a general vaccine were used as controls. After 3 days,
cells were pulsed with 2 Ci 3H-thymidine/well and were cultured
for another 18 hours. Results are given as stimulation index (mean
counts per minute [cpm] of culture with antigen/mean cpm of
culture with medium)standard error.
Cytokine and Chemokine Measurement
Tissue culture supernatants were collected every 24 hours from
days 1 to 3 after stimulation (see proliferation assay). Cytokines of
pooled samples were measured with the Bio-Plex protein array
system (Bio-Rad Laboratories, Inc., Hercules, CA) in combination
with Bio-Plex Manager software, which is designed for the mul-
tiplexed quantitative analysis of multiple cytokines and chemo-
kines in a single well. Premixed multiplex beads for interleukin
(IL)-2, interferon (IFN)-, tumor necrosis factor-, IL-4, IL-10,
IL-17, IL-6, IL-8, MIP-1a, and granulocyte-monocyte colony-
stimulating factor with a detection limit of 5 pg/ml in 50 l total
test volume were used and the assay was performed following the
manufacturer’s instructions. Only amounts of more than 10 pg/ml
ite circle) that had remained unchanged for 7 years in a location atypicalr (whwere regarded as a specific response.
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In Vitro Lymphocyte Responses
The patient’s lymphocytes were collected when clinical disease
had subsided completely. Proliferation exceeding the medium con-
trol by 2-fold was observed only for PPD, TT, IRBP, and R16 (Fig
3). Elevated cytokine responses were detected more frequently,
revealing T-helper 1 (Th1)-type reactivity with secretion of IFN-
to all tested retinal antigens and peptides from S-Ag and IRBP as
well as to chicken ovalbumin and PPD (Fig 3). Despite the
negative tuberculin skin response of the patient, high IL-2 secre-
tion was observed in response to PPD, but not to the other tested
antigens (Fig 3), whereas no IL-10 secretion was measured even in
cultures stimulated with PPD (data not shown). Tumor necrosis
factor- secretion was induced by R16 and CRALBP as well as by
PPD, whereas no IL-4, the typical cytokine of the T helper 2 type,
was found in either culture. Variable high levels of at least 200
pg/ml IL-6 were found in all cultures except the medium control,
whereas IL-8 levels exceeding the medium control by at least two
fold were obtained only after stimulation with PPD, PepM, PI731,
and R4/R14. In contrast, MIP1-a was secreted in all cultures, with
very low levels in response to PepM, PI536, PI1137, R14, and
PDIRBP. Granulocyte-monocyte colony-stimulating factor was
detected in all supernatants except medium control in levels be-
tween 36 and 290 pg/ml, whereas IL-17 was not found in any
Figure 3. Graphs showing in vitro responses of patient lymphocytes to re
retinoid-binding protein [IRBP] and peptides, cellular retinal-binding p
derivative [PPD]). Values exceeding the diagram size are printed in the
MIP  macrophage inflammatory protein; OVA  chicken ovalbumin; P
M of S-Ag; TNF  tumor necrosis factor; TT  tetanus toxoid.culture supernatant (data not shown). Except for PPD responses,
2460there was no correlation between lymphocyte proliferation and
cytokine or chemokine secretion.
Comparison of the amino acid sequences of retinal proteins and
peptides that induced the highest Th1 responses with the sequences
of BCG proteins resulted in several highly similar or even identical
regions of 5 to 11 amino acids (Fig 4, available at http://aaojournal.
org). These epitopes might have been responsible for a crossreactivity
of the patient’s BCG-specific T cells with retinal autoantigen, result-
ing in uveitis. For the in vitro stimulation, we used bovine proteins
with few amino acid differences from the human protein, the potential
antigen for the patient’s autoimmune response. Four alignments with
S-Ag protein were found, which are not covered by any of the
peptides and 4 homologies with peptide SAg281, which induced the
highest cytokine and chemokine responses of all S-Ag peptides. In
addition to alignments with peptide R16 and R4T, 5 homologies with
the sequence of IRBP protein were detected that are not represented
by any of the peptides, and in addition, 2 similarities with CRALBP
protein were found. The homologous sequences were from different
proteins of BCG, indicating that a variety of different antigens could
induce crossreactivity.
Discussion
Bacille Calmette-Guérin instillation is regarded as the most
antigens (retinal soluble antigen [S-Ag] and peptides; interphotoreceptor
[CRALBP]; ovalbumin and tetanus toxoid, as well as purified protein
ctive columns. IFN  interferon; IL  interleukin; Med  medium;
P  peptide D of IRBP; PDSAg  peptide D of S-Ag; PepM  peptidetinal
rotein
respe
DIRBeffective treatment and prophylaxis for noninvasive bladder
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tumor cells using fibronectin and integrins and induce in-
flammation with infiltration of macrophages, T and B lym-
phocytes, and natural killer cells as well as upregulation of
proinflammatory cytokines including IL-1, IL-2, IL-5, IL-6,
IL-8, IL-10, IL-12, IL-18, IFN-, tumor necrosis factor-, and
granulocyte-monocyte colony-stimulating factor.14,18–20 Over-
all, a T-helper–type 1 immune response is generated that
mediates a local antitumor activity, and in addition, tumor
cell mobility is inhibited. This local response also induces
systemic reactions, including increased specific T-cell pro-
liferation and antibody production.21,22
This therapy also has some immune-mediated side effects,
mainly arthritis and uveitis.4,6–11,23–26 Compared with the
number of patients treated for carcinoma with BCG or vacci-
nated against tuberculosis, the incidence of autoimmune dis-
eases arising as adverse effects is very low. The reason why
autoimmune diseases develop after BCC treatment in some
patients could be based on genetic predispositions such as the
presence of certain HLA antigens. The patient was negative for
HLA-B27 but positive for HLA-B8 and HLA-B38. HLA-B8 is
associated with uveitis in black Americans and is more fre-
quent in sarcoidosis than in tuberculosis patients, suggesting a
role of HLA-B8 in autoimmunity.27,28
M. tuberculosis infection of ocular tissues results in
uveitis; however, intraocular infection is not necessary. Sys-
temic infection with M. tuberculosis may cause inflamma-
tion of the eye by a cross-reactive immune response, as
observed here after BCG therapy, when T cells recognize
mycobacterial antigens as well as ocular proteins. This
phenomenon, called antigenic mimicry, was a presumed
cause of previously reported uveitis.5,29 Thus, the patient’s
peripheral T-cell response to PPD and a set of retinal
autoantigen proteins and peptides were investigated. Al-
though the patient, according to her own statement, had no
positive skin reaction to tuberculin (PPD), a strong in vitro
response to PPD with respect to proliferation and Th1-type
cytokine production (IL-2, IFN-, tumor necrosis factor-)
was observed. The Tine test is an intracutaneous prick test
that can give false-negative results because of insufficient
antigen application. Furthermore, proliferative or cytokine
responses, or both, were detected to 3 retinal autoantigens
(S-Ag, IRBP, and CRALBP) and to some of their peptides,
which are involved in the autoimmune response of human
uveitis.17,30 Several homologies on the level of amino acid
sequence were found—even identities of up to 7 continuous
amino acids—between BCG proteins and these retinal au-
toantigens that could explain the T-cell reactivities, as we
could already previously demonstrate for peptides from
rotavirus, bovine milk casein, and retinal S-Ag peptide
PDSAg were demonstrated.29
The literature describes some M. tuberculosis peptides
that are recognized by human T cells—most of them by
CD8 cytotoxic T cells.31–35 In these cases, tuberculosis
had developed in patients after mycobacterial infection or
after they had had contact with tuberculosis patients. None
of the peptides recognized by infected individuals is iden-
tical with any of the mimicy peptides that potentially imitate
retinal autoantigens, indicating that recognition of these
mimotopes is not a common event.The recognition of certain epitopes with the subsequent
development of an autoimmune disease has a genetic basis.
The potential of peptide recognition depends on the indi-
vidual T-cell receptor repertoire and the ability of the re-
spective HLA class II molecules to bind and present the
peptides. If a strong Th1 response is elicited in an individual
with a certain genetic predisposition, there will be an enhanced
risk for the development of autoimmune disease. This study
has shown potential antigenic mimicry between mycobacterial
proteins and retinal autoantigens that likely induces an aggres-
sive immune response that targets the eye. This also may be
the initiating cause for uveitis in patients with latent disease
or active tuberculosis without intraocular infection.
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CLINICAL SCIENCES
Bilateral Acute Iris Transillumination
Ilknur Tugal-Tutkun, MD; Sumru Onal, MD, FEBOphth; Aylin Garip, MD; Muhittin Taskapili, MD;
Haluk Kazokoglu, MD; Sibel Kadayifcilar, MD; Philippe Kestelyn, MD
Objective: To describe a series of patients with bilat-
eral acute iris transillumination, pigment dispersion, and
sphincter paralysis.
Methods: We reviewed the medical records and clini-
cal photographs of 26 patients seen at 5 centers in Tur-
key and Belgium between March 16, 2006, and July 6,
2010. Observation procedures included clinical exami-
nation, anterior segment color photography, gonios-
copy, laser flare photometry, and pupillometry.
Results: All 26 patients (20 women and 6 men; mean
[SD] age, 43.2 [10.5] years) had bilateral involvement.
Twenty-three patients (88%) had acute-onset disease with
severe photophobia and red eyes. Nineteen patients (73%)
had a preceding flulike illness and used systemic antibi-
otics, including moxifloxacin. Diagnostic laboratory
workup was unremarkable. There was pigment dis-
charge into the anterior chamber, and flare was elevated
in the absence of inflammatory cells. Most patients had
severe diffuse transillumination of the iris and mydri-
atic distorted pupils. Pupillometry revealed a compro-
mised reaction to light. The most serious complication
was an intractable early rise in intraocular pressure. Go-
nioscopy revealed heavy pigment deposition in the tra-
becular meshwork. Although symptoms were relieved
promptly by application of topical corticosteroid, the me-
dian duration of pigment dispersion was 5.25 months.
Conclusions: Bilateral acute iris transillumination with
pigment dispersion and persistent mydriasis is a new clini-
cal entity that is not an ocular adverse effect of oral moxi-
floxacin treatment, as previously suggested. The etio-
pathogenesis of this entity remains to be elucidated.
Arch Ophthalmol. 2011;129(10):1312-1319
K NOWN CAUSES OF ACQUIREDiris atrophy with or with-out transilluminationof theiris include herpetic irido-cyclitis, pigment disper-
sion syndrome (PDS), pseudoexfoliation
syndrome, Fuchs uveitis syndrome, Vogt-
Koyanagi-Haradadisease, trauma,andacute
angle-closure glaucoma.1-10 Pigment dis-
charge into the anterior chamber is a diag-
nostic feature of PDS and may also occur
in pseudoexfoliation syndrome.1,2 Pig-
ment dispersion is also one of the diagnos-
tic features of the recently described entity
bilateral acute depigmentation of the iris
(BADI). However, BADI is characterized by
a nontransilluminating depigmentation of
the iris stroma.11,12 More recently, an ac-
quired bilateral diffuse iris transillumina-
tion with variable sphincter paralysis has
been described as an ocular adverse effect
oforalmoxifloxacin treatment.13-15 Wehave
seen patients with similar ocular findings
with or without a history of moxifloxacin
intake.
We herein describe the clinical fea-
tures and course in 26 patients who de-
veloped bilateral acute iris transillumina-
tion (BAIT) associated with pigment
showering and persistent mydriasis.
METHODS
Twenty-seven consecutive patients with BAIT
were seen at 4 ophthalmology clinics in Tur-
key and 1 in Belgium between March 16, 2006,
and July 6, 2010. One patient with concomi-
tantBehc¸etdiseasewasexcluded fromthestudy.
We reviewed the medical and photographic rec-
ords of the remaining 26 patients and used a
standard data acquisition form at each center
to gather retrospective data for this study. In-
formed consent of the patients was obtained
for all procedures and treatments used. The
study was approved by the ethics committee
of Istanbul Faculty of Medicine, Istanbul Uni-
versity, Istanbul, Turkey, and was conducted
according to the tenets of the Declaration of
Helsinki.
At the initial visit, adetailedocular andmedi-
cal history was obtained from each patient, in-
cluding onset of ocular complaints, previous
systemic findings, and previous treatment(s).
A complete ocular examination was con-
ducted at each visit, including best-corrected
visual acuity using a Snellen scale from 0.1 to
1.0, slitlamp biomicroscopy, tonometry, and
indirect ophthalmoscopy. Gonioscopy was per-
formed in all the patients. Corneal sensationwas
checked using a cotton yarn. Color photo-
graphsof theanteriorsegmentwere taken ineach
patient. We used the Vision Monitor WIN8000E
(Metrovision,Perenchies,France) toperformpu-
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pillometry and a laser flare photometer (KOWA FC-2000; Kowa
Co Ltd, Tokyo, Japan) to measure anterior chamber flare only in
patients seen at the Uveitis Service of the Department of Oph-
thalmology, Istanbul Faculty of Medicine, Istanbul University.
The pupil diameters were measured under photopic and scoto-
pic conditions. Pupillometry was performed in age- and sex-
matched control subjects for comparison with the retrospective
data obtained from the study patients.
Diagnostic laboratory workup included erythrocyte sedi-
mentation rate, complete blood cell count, and biochemistry.
Serum IgG and IgM antibodies against herpes simplex virus types
1 and 2, varicella zoster virus, cytomegalovirus, and/or Epstein-
Barr virus were measured in 10 patients. Patients were treated
with topical corticosteroids when they had acute symptoms or
ongoing high-grade pigment dispersion in the anterior cham-
ber. Empirical oral acyclovir or valacyclovir therapy was given
to the first 8 patients with pigment dispersion. In patients with
an intraocular pressure (IOP) higher than 21 mm Hg, topical
antiglaucomatous medications were used. If IOP exceeded 40
mm Hg, intravenous mannitol, 20%, infusions were given.
The main outcome measures were demographic features,
initial ocular and systemic symptoms, ocular clinical findings,
and pupillometry and flare photometry measurements. In pa-
tients who had resolution of pigment dispersion during follow-
up, time to resolution was also determined.
We used a commercially available statistical analysis pro-
gram (SPSS, version 16.0 for Windows; SPSS Inc, Chicago, Il-
linois) for analysis of the data. The Mann-Whitney, Wil-
coxon, and Kruskal-Wallis tests were used to test for differences
between groups. The Dunn test was used as a multiple com-
parison post hoc test. Categorical data were analyzed by the 2
test. P .05 was considered significant.
RESULTS
Twenty patients were women and 6 were men. The mean
(SD) patient age when first seen was 43.2 (10.5) years
(median, 42 years; age range, 25-69 years). Seven pa-
tients were seen only once or had follow-up of less than
1 month. The remaining 19 patients had mean (SD) fol-
low-up of 13.2 (12.2) months (median, 9.7 months; range,
1.5-43.0 months). All the patients had bilateral involve-
ment. The demographic and clinical characteristics of the
patients at the first visit are given in Table1 and in eTable
1 and eTable 2 (http://www.archophthalmol.com).
INITIAL OCULAR SYMPTOMS
AND OCULAR HISTORY
All the patients had an acute onset of ocular symptoms.
Twenty-three patients (88%) had or reported an acute
onset of severe photophobia and red eyes. Three pa-
tients reported only red eyes. Both eyes were involved
simultaneously; however, symptom severity could be
asymmetrical. Seven patients were seen within 1 week
of onset of ocular symptoms. The remaining 19 patients
were referred with a diagnosis of iridocyclitis with un-
usual features. The median disease duration in the latter
group was 2 months (range, 2 weeks to 14 months). All
these patients had been treated with topical corticoste-
roids. Five patients reported systemic corticosteroid use,
and 7 patients had been given oral antiviral medica-
tions. Twelve patients (63%) had a history of IOP rise,
bilaterally in 10. All these patients had been treated with
topical antiglaucomatous medication(s) and 6 with con-
comitant oral acetazolamide. One patient had under-
gone trabeculectomy in 1 eye 7 months after onset of the
disease. Another patient had required intravenous infu-
sion of mannitol, 20%, to control the IOP rise. Ocular
history was otherwise unremarkable.
SYSTEMIC SYMPTOMS AND MEDICAL HISTORY
Nineteen patients (73%) reported a flulike illness or up-
per respiratory tract infection preceding the onset of ocu-
lar symptoms. The mean (SD) interval between the on-
Table 1. Demographic Features and Initial Clinical Findings
of 26 Patients (52 Eyes) With Bilateral Acute Iris
Transillumination
Characteristic Description
Age, mean (SD) [range], y 43.2 (10.5) [25-69]
Sex, No. (%)
Female 20 (77)
Male 6 (23)
Initial symptoms, No. (%)
Red eyes 26 (100)
Photophobia 23 (88)
Ocular pain 10 (38)
Blurred vision 7 (27)
Laterality, No. (%)
Bilateral 26 (100)
Unilateral 0
Visual acuity, median (SEM) [range]
Right eye 1.0 (0.03) [0.3-1.0]
Left eye 1.0 (0.03) [0.4-1.0]
Patients; eyes with, No. (%)
Conjunctival hyperemia 7 (27); 12 (23)
Pigment keratic precipitates 12 (46); 21 (40)
Circulating pigment in the AC 23 (88); 45 (87)
Transillumination 26 (100); 52 (100)
Bilateral diffuse 21 (81); −
Diffuse in 1 eye and moth-eaten in
the other eye
4 (15); −
Bilateral moth-eaten 1 (4); −
Mydriatic pupil with sphincter paralysis −; 46 (88)
Irregular distorted pupil 20 (77); 32 (62)
Posterior synechiae 3 (12); 4 (8)
Iris color, No. (%) of patients
Brown 23 (88)
Blue 2 (8)
Green 1 (4)
IOP, mean (SD) [range], mm Hg
Right eye 16.57 (5.85) [9-37]
Left eye 18.80 (7.82) [8-41]
AC flare measured in 18 patients, mean
(SD) [range], ph/ms
(1) In 10 eyes with no pigment to
0.5 pigment in the AC
6.08 (2.94) [3.50-13.00]
(2) In 14 eyes with 1 to 2
pigment in the AC
12.08 (9.19) [3.90-33.00]
(3) In 12 eyes with 3 to 4
pigment in the AC
169.99 (151.77) [2.60-448.20]
Kruskal-Wallis 10.31
P value .005
Comparisons 13a; 23b
Abbreviations: AC, anterior chamber; IOP, intraocular pressure; ph/ms,
photon count per millisecond; minus, negative.
aP .01 by Dunn test.
bP .05 by Dunn test.
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set of systemic symptoms and the onset of ocular disease
was 2.52 (1.46) weeks (median, 2 weeks; range, 1-6
weeks). All these patients had been treated with sys-
temic antibiotics, including moxifloxacin in 9 (35%), am-
picillin-sulbactam in 2 (8%), amoxicillin-clavulanate in
2 (8%), and trimethoprim-sulphamethoxazole, cefix-
ime, and penicillin V in 1 (4%) each. Three patients could
not recall the name of the antibiotic they had used. In 7
patients (27%), the medical history was unremarkable.
RESULTS OF THE LABORATORY WORKUP
Routine laboratory results were within the reference
ranges. Viral serologic analysis in 10 patients showed that
the IgM antibodies were negative and the IgG antibod-
ies were not elevated. In patients tested for IgG antibod-
ies against herpes simplex virus type 1 and Epstein-Barr
virus, seropositivity was 83% and 75%, respectively. All
patients tested for anti−varicella zoster virus and cyto-
megalovirus were found to have positive IgG antibod-
ies. No patient was found to have IgG positivity against
herpes simplex virus type 2.
INITIAL OCULAR FINDINGS
Median visual acuity was 1.0 OU (range, 0.3-1.0 OD and
0.4-1.0 OS). Reduced visual acuity was due to amblyo-
pia in 2 eyes. Another eye with visual acuity of 0.3 had a
preretinal hemorrhage at the posterior pole that had oc-
curred after trabeculectomy.
Conjunctival hyperemia was documented in the 7 pa-
tients (12 eyes) who were first seen within 1 week of the
onset of ocular symptoms. Fine pigment precipitates on
the corneal endothelium were recorded in 12 patients (21
eyes): in the form of Krukenberg spindle in 2 (4 eyes),
diffusely scattered in 3 (6 eyes), and distributed in the
lower half of the cornea in 7 (11 eyes). Inflammatory ke-
ratic precipitates were not seen.
None of the patients had inflammatory cells in the an-
terior chamber at the first visit or during follow-up. There
was variable pigment dispersion in the anterior chamber
in both eyes of 22 patients. Three patients who were first
seen 4 months to 1 year after the onset of ocular symp-
toms had no circulating pigment in the anterior chamber
but had diffuse transillumination of the iris and persis-
tent mydriasis due to sphincter paralysis in both eyes. An-
other patient who was first seen on day 5 of the onset of
ocular disease had 4 pigment in the left eye only. How-
ever, pigment dispersion occurred in the other eye dur-
ing follow-up but did not exceed 0.5. The iris of this pa-
tient exhibited diffuse transillumination in the left eye and
only moth-eaten transillumination in the right eye.
Twenty-one patients (42 eyes) had severe diffuse trans-
illumination of the iris and mydriatic pupils poorly re-
sponsive or unresponsive to light (Figure 1 and Ap-
pendix [eCase 1]). In 4 patients, there was asymmetrical
involvement, with diffuse transillumination in 1 eye with
a mydriatic pupil and less severe, moth-eaten transillu-
mination without apparent mydriasis in the other eye.
One patient had symmetrical bilateral moth-eaten trans-
illumination with normal pupils. An irregular distorted
pupil was also noted in 20 patients (32 eyes). Spiraling
of the pupil was not apparent. Posterior synechiae were
documented in 3 patients (4 eyes). The morphologic fea-
tures of posterior synechiae were different from those of
uveitic synechiae in that a thick layer of iris pigment
seemed to be smeared on the surface of the lens and re-
mained adherent with a broad base (Figure 2). In 10
patients (19 eyes), smeared iris pigment (Figure 1) or pig-
ment dusting (Figure 3 and Appendix [eCase 2]) was
seen on the surface of the lens. Scattered pigment par-
ticles were seen on the surface of the iris as well. One
patient had unilateral mild posterior subcapsular lens
opacity. The corneal sensation was intact, and the vitre-
ous was clear in all the patients. The fundus was normal
in all except 1 patient with preretinal hemorrhage at the
posterior pole after trabeculectomy in 1 eye.
Mean IOP values are given in Table 1. An IOP higher
than 21 mm Hg was measured in 8 patients (11 eyes). Nine
patients were still taking topical antiglaucomatous medi-
A B
C D
Figure 1. A 44-year-old woman (eCase1). The mydriatic pupils are poorly
responsive to light in the right (A) and left (B) eyes. Severe diffuse iris
transillumination is evident in the right (C) and left (D) eyes on retroillumination.
Note the smeared iris pigment on the surface of the lens (A-D). The
photographs were taken without pharmacologic dilation of the pupils.
Figure 2. A 34-year-old man showing posterior synechiae with a broad base
and a thick layer of iris pigment smeared on the surface of the lens. The pupil
is mydriatic and unresponsive to light. The photograph was taken without
pharmacologic dilation of the pupil.
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cation(s), and 4 of them were receiving concomitant oral
acetazolamide therapy prescribed elsewhere. On gonios-
copy, none of the eyes had an occludable angle. There was
heavy pigment deposition especially in the inferior angle
in all the patients. The amount of pigment deposition in
the angle was asymmetrical in some patients.
Laser flare photometry was performed at the initial visit
in 18 patients (36 eyes). Eyes with 3 to 4 pigment had
significantly elevated mean laser flare photometry read-
ings compared with those with none to 0.5 pigment
(P .01) and those with 1 to 2 pigment (P .05).
PUPILLOMETRY FINDINGS
Pupillometry was performed in 15 patients and 20 con-
trols (Table 2). Sex and mean age did not differ be-
tween the 2 groups. Under scotopic conditions, no sig-
nificant difference was noted in pupil diameter between
patients and controls (P=.62 for right eyes and P=.85 for
left eyes); however, under photopic conditions, pa-
tients’ mean pupil diameter was significantly larger
(P .001 for right and left eyes). Patients had signifi-
cantly reduced amounts of miosis. Pupillary reaction to
near stimuli was also compromised. Accommodation was
not measured in any patient; however, none of the pa-
tients required additional plus lenses for near vision.
TREATMENT AND FOLLOW-UP
Treatment and follow-up are summarized in eTable 2.
Seven patients who were first seen within 1 week of the
onset of ocular symptoms were treated with hourly topi-
cal corticosteroid application, which resulted in prompt
relief of their symptoms. Seven patients who were re-
ferred 1 to 14 months after disease onset and had less than
2 pigment and low flare (15 photon counts per mil-
lisecond [ph/ms]) were not given topical corticosteroids.
Topical corticosteroid therapy prescribed elsewhere was
maintained in 12 patients who were referred with a dis-
ease duration of 2 to 16 weeks and ongoing pigment dis-
persion. Four of them did not return for follow-up. Two
of them with flare measurements exceeding 150 ph/ms were
also given oral prednisolone (0.5 mg/kg/d), which was ta-
pered and discontinued within 6 weeks. The mean (SD)
duration of topical corticosteroid treatment was 3.51 (2.00)
months (median, 3 months; range, 1-8 months). In 11 pa-
tients, topical corticosteroid therapy was discontinued with
slow tapering, and no relapse was seen. Only 1 patient had
2 relapses during tapering, which were controlled with an
increased dose and successful discontinuation of treat-
ment at 5 months. Mean (SD) follow-up after withdrawal
of treatment in these 12 patients was 13.6 (12.4) months
(median, 9.12 months; range, 1-39 months).
Mean (SD) time from onset of ocular symptoms to com-
plete resolution of pigment dispersion in the anterior cham-
ber was 7.30 (5.68) months (median, 5.25 months; range,
1-18 months) in 14 patients (28 eyes). Resolution of pig-
ment dispersion in the anterior chamber occurred simul-
taneously in both eyes in all except 2 patients. The mean
(SD) flare was significantly reduced at the last visit (from
39.23 [73.44] to 5.18 [3.03] in right eyes, P=.02; and from
81.92 [132.66] to 4.52 [1.13] in left eyes, P=.002).
Two of the 7 patients who were first seen by us de-
veloped high IOP during follow-up. The IOP was raised
within 1 week in both eyes of 1 patient and at 2 months
in 1 eye of the other patient. None of the referred pa-
tients who did not have a history of IOP rise developed
this complication during follow-up. Thus, 14 patients
(54%) had IOP rise during the disease course, and 10 re-
ceived antiglaucomatous medication(s) during follow-
up. The mean (SD) duration of topical antiglaucoma-
tous therapy was 9.25 (8.16) months (median, 8.5 months;
range, 1 month to 3 years). Seven patients required con-
comitant oral acetazolamide therapy, and 5 patients re-
quired intravenous infusion(s) of mannitol, 20%. Two
patients with high IOP despite maximum-tolerated medi-
cal therapy required bilateral trabeculectomy combined
with mitomycin application 3 to 9 weeks after disease on-
set. Both of these patients had 4 pigment in the ante-
rior chamber before surgery, and a dense pigment accu-
mulation occurred inside the bleb (Figure4). The mean
(SD) final IOP was 14.15 (2.87) mm Hg (range, 10-20
mm Hg) in right eyes and 14.20 (3.07) mm Hg (range,
8-21 mm Hg) in left eyes. Six patients were still taking
topical antiglaucomatous medication(s) at the final visit.
None of the patients developed glaucomatous optic disc
changes or visual field defects.
Bilateral cataract developed in 7 patients. After reso-
lution of pigment dispersion, 4 eyes underwent unevent-
ful phacoemulsification and intraocular lens implanta-
tion. Visual acuity was well preserved. Median final visual
acuity was 1.0 OU (range, 0.4-1.0 OU). Visual acuity de-
creased to 0.4 in 1 eye due to cataract formation.
COMMENT
We described 26 patients with an unusual bilateral acute
iris transillumination associated with symptomatic pig-
ment showering after a flulike illness or an upper respi-
ratory tract infection in most cases. Middle-aged women
are more commonly affected. Despite the absence of in-
flammatory keratic precipitates or cells in the anterior
chamber, pigment storm is associated with a flare rise,
Figure 3. A 25-year-old woman showing pigment dusting on the surface of
the lens (eCase2). The pupil is mydriatic and unresponsive to light. The
photograph was taken without pharmacologic dilation of the pupil.
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and patients may be misdiagnosed as having acute bilat-
eral iridocyclitis. Clinical findings that challenge con-
ventional diagnosis include bilateral severe transillumi-
nation of the iris, pigment dispersion in the anterior
chamber, and a mydriatic pupil that is unresponsive or
poorly responsive to light due to variable sphincter pa-
ralysis. Symptoms are rapidly responsive to topical cor-
ticosteroid therapy; however, pigment dispersion may last
months and even up to more than 1 year. An early rise
in IOP is a common complication and can be refractory
to treatment. The etiology remains unknown.
There are recent reports on the occurrence of acute
pigment dispersion and iris transillumination after oral
moxifloxacin treatment. Bilateral abundant pigment dis-
persion has been reported as a complication of moxi-
floxacin used for the treatment of pneumonia.13 More re-
cently, Wefers Bettink-Remeijer et al14 described 5 patients
who had an acute onset of photophobia and pain fol-
lowed by bilateral diffuse iris transillumination with vari-
able sphincter paralysis and concluded that this was an
ocular adverse effect of oral moxifloxacin use. Most pa-
tients in the present cohort had a preceding flulike ill-
ness or respiratory tract infection before the onset of ocu-
lar symptoms; although only approximately 35% reported
moxifloxacin intake, 40% were exposed to other antibi-
otics. Therefore, we believe that the clinical picture de-
scribed herein may represent a distinct condition prob-
ably triggered by a viral infection. Theoretically, such an
ocular adverse effect would also be expected to occur with
the topical application of moxifloxacin, which has been
shown to have efficient ocular penetration.16 To our
knowledge, there is no such reported ocular adverse effect
of topical moxifloxacin treatment.
The differential diagnosis of BAIT is summarized in
Table 3. Pigment dispersion syndrome is the most dif-
ficult to differentiate from the entity described herein. Se-
Table 2. Comparison of Demographic Features and Pupil Diameters in Patients and Control Subjects
Variable
Patients
(n=15)
Control Subjects
(n=20) P Valuea
Demographic features
Sex, F/M, No. 10/5 14/6 .83b
Age, mean (SD) [range], y 43.0 (12.4) [25 to 69] 40.1 (8.8) [26 to 58] .52
Pupil diameter, mm OD OS OD OS OD OS
Photopic
Mean (SD) 3.84 (0.97) 4.12 (1.08) 2.41 (0.21) 2.29 (0.13)
.001 .001Median (SEM) 3.80 (0.25) 4.20 (0.27) 2.35 (0.04) 2.25 (0.03)
Range 2.4 to 5.6 2.3 to 5.4 2.2 to 3.1 2.2 to 2.7
Scotopic
Mean (SD) 5.04 (0.87) 4.89 (0.98) 5.19 (0.77) 5.05 (0.62)
.62 .85Median (SEM) 4.90 (0.22) 5.20 (0.25) 5.10 (0.17) 5.15 (0.14)
Range 3.3 to 6.4 2.6 to 6.4 3.9 to 6.6 3.9 to 6.2
Miosis, mm
Mean (SD) 1.20 (1.24) 0.77 (0.90) 2.78 (0.69) 2.75 (0.58)
.001 .001Median (SEM) 0.90 (0.32) 0.40 (0.23) 2.80 (0.15) 2.90 (0.12)
Range −0.20 to 3.9 −0.6 to 2.7 1.5 to 4.0 1.5 to 3.5
aMann-Whitney test.
b2= .04.
A B
Figure 4. A 53-year-old man who underwent left trabeculectomy combined with mitomycin application 9 weeks after disease onset because of high intraocular
pressure despite maximum-tolerated medical therapy. A, Dense pigment accumulation occurred inside the bleb 3 months after surgery. B, Severe diffuse iris
transillumination and a mydriatic pupil unresponsive to light are also evident. A peripheral iridectomy is discernable at the 12-o’clock position. The photographs
were taken without pharmacologic dilation of the pupil.
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vere photophobia and markedly red eyes, as seen in the
present series, are not characteristic of PDS. Patients de-
scribed herein developed severe diffuse iris transillumi-
nation at a single episode and did not have a midperiph-
eral radial spokelike pattern, which typically develops over
a chronic progressive course in PDS. Ocular hyperten-
sion or pigmentary glaucoma develops over years in PDS,17
whereas the IOP rise occurred within weeks to months in
the present series. Pupillary reactions to light and near
stimuli are not affected in PDS.18,19 Compromised pupil-
lary constriction to light was thought to be related to vari-
able amounts of sphincter paralysis in the present pa-
tients. Posterior bowing of the iris is a characteristic feature
of PDS.1 Willermain et al15 described a patient with bilat-
eral symptomatic acute iris transillumination, pigment dis-
persion, and severe IOP rise after moxifloxacin use. Go-
nioscopy revealed heavy pigment deposition in the
iridocorneal angle, and anterior segment optical coher-
ence tomography showed iris concavity in their patient.15
Because iris concavity is a typical finding in PDS, their pa-
tient probably had PDS and an acute elevation in IOP due
to the use of subconjunctival corticosteroids. Although we
did not perform anterior segment optical coherence to-
mography or ultrasound biomicroscopy, we do not have
any clinical observation of iris concavity or posterior bow-
ing in any patient. This finding has not been reported by
other researchers either.13,14
Pigment dispersion is also one of the diagnostic fea-
tures of the recently described entity BADI, which is char-
acterized by nontransilluminating depigmentation of the
iris stroma and pigment discharge into the anterior cham-
ber. Common features of BADI and the condition de-
Table 3. Differential Diagnosis of BAIT
Characteristic
Herpetic
Iridocyclitis3,4 FUS5,6 PXF2 BADI11,12 PDS1,17-19 BAIT
Sex No predilection No predilection Commonly female Female predominance
(2.7:1)
Mostly male Female
predominance
(3.3:1)
Symptoms at onset Symptomatic, with red
eyes, ocular pain,
and photophobia
Asymptomatic Asymptomatic Severe photophobia
and red eyes
Usually
asymptomatic;
occasionally
headache, blurred
vision, and halos
around light during
pigment showering
Severe photophobia
and red eyes
Laterality Typically unilateral Typically unilateral Bilateral
asymmetrical
Bilateral symmetrical Bilateral, mostly
symmetrical
Bilateral, mostly
symmetrical
Keratic precipitates Inflammatory Inflammatory, diffuse
stellate, and
medium sized
Pigment Pigment Pigment Pigment
Krukenberg spindle None None None Sometimes present Present Sometimes present
Pigment particles in
the AC
None None Sometimes
present
Present Present Present
Inflammatory cells
in the AC
Present during
exacerbations
Chronic, low grade None None None None
Iris
transillumination
Patchy or sectoral Rarely peripupillary Peripupillary None Midperipheral
spokelike
Diffuse
Change in the iris
configuration
None None None None Posterior bowing None
Iris stromal
changes
Patchy or sectoral
stromal atrophy
Diffuse stromal
atrophy with
blunting of iris
crypts with or
without
heterochromia
None Bilateral symmetrical
geographic or diffuse
depigmentation and
granularity with
distinct margins
None None
Pupillary changes Usually present,
irregular distorted
pupil with spiraling
Rarely anisocoria,
with larger pupil on
the affected side
None None Anisocoria in
asymmetrical
cases, with
preserved light and
near response
Present; usually
symmetrical,
dilated atonic pupil
with compromised
reaction to light
and near stimuli
IOP rise Acute and transient
during exacerbations,
related to trabeculitis
Frequent
complication
developing over
years
Frequent
complication
developing over
years
Uncommon, transient Frequent complication
developing over
years
Early complication,
resistant
Gonioscopy Open angle Open angle, new
vessels,
occasionally
goniosynechiae
Pseudoexfoliation
material
Pigment deposition Pigment deposition Pigment deposition
Abbreviations: AC, anterior chamber; BADI, bilateral acute depigmentation of the iris; BAIT, bilateral acute iris transillumination; FUS, Fuchs uveitis syndrome;
IOP, intraocular pressure; PDS, pigment dispersion syndrome; PXF, pseudoexfoliation syndrome.
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scribed herein include an acute onset of severe photo-
phobia and red eyes after a flulike syndrome, pigment
discharge into the anterior chamber, and exclusive in-
volvement of the iris. Oral antibiotic drug use was re-
ported in 38.5% of patients with BADI, including moxi-
floxacin use in 30.7% and amoxicillin-clavulanate use in
7.7%.12 Even if BAIT may be a more severe form of BADI
and both conditions have a common etiology, the pig-
ment discharge seems to be only from the iris pigment
epithelium in the former and from the iris stroma in the
latter. The most important differentiating feature be-
tween the 2 entities is that the pupil is not affected in BADI
and a symmetrical geographic or diffuse depigmenta-
tion of the iris stroma causes a change in iris stromal tex-
ture and color without any transillumination defect,11,12
whereas patients described herein typically had atonic
dilated pupils and diffuse iris transillumination without
any visible change to the iris stroma. Furthermore, BADI
has a more benign course with a shorter duration of pig-
ment discharge, a lower incidence of IOP rise that is only
transient, and reversibility of iris changes reported at least
in some patients.11,12 Heavy pigment deposition in the tra-
becular meshwork was a consistent finding in the pres-
ent series and explained the early severe IOP rise that could
occur as early as 1 week and the need for trabeculec-
tomy as early as 3 weeks after onset. On the other hand,
a corticosteroid-induced IOP rise cannot be excluded in
patients who developed this complication later on.
The present patients clearly differed from those with
pseudoexfoliation syndrome, Fuchs uveitis syndrome, and
herpetic anterior uveitis. Sectoral iris atrophy with chronic
refractory glaucoma may rarely be seen in immunocom-
petent patients with cytomegalovirus anterior uveitis.20-22
Aqueous humor analysis for local antibody production or
demonstration of viral DNA is needed for a definite diag-
nosis of viral etiology. Diffuse iris atrophy has been re-
ported in 50% and elevated IOP in 100% of eyes diag-
nosed as having cytomegalovirus anterior uveitis.20
However, in those eyes, diffuse iris transillumination and
sphincter paralysis have not been described.20 Anterior
chamber tap was reported to be negative for herpes vi-
ruses in 5 of the 6 cases previously reported in the litera-
ture with findings similar to the present series, and the her-
pes virus genome was found in only 1 patient, who had a
history of uveitis.14,15 The causative agent of the preced-
ing systemic illness is not known in any of the present pa-
tients. With the emergence of new respiratory viruses, new
disease entities may develop, and conjunctiva may not be
the only ocular tissue affected by these infections.23 Al-
though we presume that the entity described herein might
be related to a systemic viral infection, the pathogenesis
of iris involvement remains elusive. Because we could not
perform iris angiography, we could not exclude iris ische-
mia as a possible cause of irreversible damage to the iris
pigment layer and the pupillary sphincter. Ischemic iris
changes have been reported to occur in 52.5% of cases af-
ter an episode of angle-closure glaucoma.10 Although an
iris ischemia may be caused by an episode of angle-
closure glaucoma precipitated, for example, by the use of
vasoconstrictors during a flulike illness, gonioscopy did
not reveal occludable angles in any eye in this series. More-
over, an elevated IOP was not reported at the onset of the
disease in any of the referral cases, and the IOP was low to
normal in patients who were seen first by us.
This study is limited by its retrospective nature, lack
of intraocular fluid analysis, unavailability of iris angi-
ography, and variable treatment and follow-up. We re-
gret that iris specimens obtained by iridectomy in pa-
tients who underwent trabeculectomy were not sent to
the laboratory for histologic analysis, culture, and other
studies that could have shed light on the etiopathogen-
esis of this condition.
In conclusion, we described an unusual condition with
symptoms masquerading as acute iridocyclitis and ocu-
lar findings bearing similarities to PDS. An acute onset of
severe photophobia and red eyes after a flulike illness or
upper respiratory tract infection is the typical presenta-
tion. Bilateral severe iris transillumination, an abundant
pigment discharge into the anterior chamber, and atonic
and distorted pupils are the constellation of findings dis-
tinct for this condition. This may be a new entity or may
represent an expanded spectrum of BADI. Even if the lat-
ter is true, prompt recognition of this condition is essen-
tial because of the high risk of early severe IOP rise.
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From the Archives of the ARCHIVES
M aher (348, On the treatment and prognosis ofprimary glaucoma). The author aims at a cys-
toid scar. He draws out a large loop of iris and allows
the wound to heal before he excises the iris. . . .
In many cases an iris encleisis, even if it does not lead
to septic infection, provides a bridge along which endo-
thelial cells proliferate till they reach the iridic angle which
they block and cause a glaucoma which is beyond treat-
ment. Lagrange’s and Herbert’s methods are far prefer-
able in every way. Most surgeons carefully avoid if pos-
sible any iris encleisis, which is recognized to be a potent
cause of failure. The author only recommends his op-
eration for chronic cases.
Source:Coburn EB. Report of the proceedings of the sec-
tion on ophthalmology of the New York Academy of
Medicine. Arch Ophthalmol. 1911;40:311.
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	5.  Discussion 
5.1. Uveitis in a patient treated with Bacille-Calmette-Guérin: Possible Antigenic Mimicry of 
Mycobacterial and retinal Antigens  
A good example to this immune stimulation called antigen mimicry is the case of bilateral uveitis after 
the intravesical Bacille-Calmette-Guérin (BCG) therapy due to bladder carcinoma. BCG is a non-
pathogenic strain of Mycobacterium bovis, which was also used for vaccine preparations 55.  
 
The Bacille-Calmette-Guérin (BCG) has been used for routine vaccination against tuberculosis since 
1921 56. In a prospective study Turnbull et al. have shown in 918 subjects (age range 1 day- 54 years) 
only in 45 vaccines an adverse reaction was reported 56. Those adverse reactions included abscess 
formation (2.5%), lymphadenitis (1%), severe local reaction (1.5%), and other reactions (pronounced 
scars, marked redness and fever) (0.7%) 56. Of the 23 abscesses, only 7 needed a treatment (2 with 
surgical excision, 3 with antibiotics, 2 with symptomatic treatment) 56. All others resolved 
spontaneously. Of 10 vaccines with lymphadenitis, only 1 was treated with antituberculosis treatment, 
all others resolved spontaneously. 3 cases with severe local reactions including pain, redness, or 
swelling received antibiotic treatment 56.  
 
Another rare adverse effect of BCG vaccination is ocular inflammation. In 1991 Yen and Liu 57 reported 
the first case of bilateral optic neuritis following BCG vaccination. Following this case report, Hegde et 
al 58 reported in 2004 another case report of a 14 year-old girl having a bilateral panuveitis and optic 
neuritis 5 weeks after the BCG vaccination. The last report to date was in 2008 from Spratt et al.59 
about a 13 year old girl, who developed bilateral chronic anterior uveitis following BCG vaccination. 
The authors speculated that the BCG-induced ocular inflammation was caused by the mechanism of 
molecular mimicry 59.  
 
BCG is also one of the most effective treatment and prophylaxis for non-invasive bladder carcinoma.  
In 2002 the worldwide estimated new cases of bladder carcinoma were 357.000 and 145.000 resulted 
with death due to the bladder carcinoma. This makes this disease the 9th most common malignancy 
and the 13th worldwide most common cause of cancer death 60.  
 
For the management of the superficial bladder carcinoma, there are several immunological agents and 
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	chemotherapeutics used intravesically. Immunotherapy with BCG was first reported in 1976 and since 
then it was used worldwide 61. Shelley et al.62 have reported in 2001 a meta-analysis of the published 
data on the randomized controlled trial with BCG. He showed that in total 585 patients included in 6 
randomized controlled trials with BCG, tumor recurrence was significantly reduced (at 12 months 67%) 
in patients receiving TUR (transurethral resection) plus BCG in comparison to the patients, who 
received TUR only 62. In the intravesical treatment with BCG, live mycobacteria attach to and invade 
the tumor cells using fibronectin and integrins and induce a T-helper-type 1 immune response 63. This 
local response also induces systemic reactions including increased specific T-cell proliferation and 
antibody production 64, 65. 
 
Intravesical BCG is well tolerated in more than 95% of the cases 66. Most of the symptoms including 
increased urinary frequency and burning, mild malaise, and low-grade fever are due to the immune 
stimulation, which is needed to effectively eradicate the cancer cells 66. Lamm had published a review 
of 23 controlled chemotherapy studies involving 4013 patients in 2000 66. The most common side effect 
seen in those patients was fever in 2,9% of the cases. The other adverse effects were granulomatous 
prostatitis (0,9%), pneumonitis and/or hepatitis (0,7%), arthralgia (0,5%), hematuria (1,0%), rash 
(0,3%), urethral obstruction (0,3%), epididymitis (0,4%), contracted bladder (0,2%), renal abscess 
(0,1%), sepsis (0,4%), and cytopenia (0,1%) 66. The patients with the evidence of BCG infection 
(epididymitis, hepatitis, or prostatitis) are treated with isonazid and rifampin 600 mg daily 66. The most 
dangerous adverse effect is the systemic septic reaction or a hypersensitivity reaction due to BCG 66.  
 
In 2000, Wittes had published a hypothesis for the immunological mechanism of BCG 67. According to 
his hypothesis first, BCG attaches to the bladder mucosa with fibronectin receptors in lamina propria. 
Then the macrophages phagocytose the bacteria and BCG is presented to regional lymph nodes. Then 
the activation of regional T lymphocytes occur and the secretion of various cytokines take place. It is 
followed by up-regulated expression of HLA-DR (i.e., MHC class II) antigen on the tumor cells and on 
the adjacent urethelium. According this hypothesis cytotoxic T cells, which recognize the co-expression 
of HLA and BCG antigens, kill the tumor cells and the adjacent urethelium. Therefore Wittes speculates 
that this mechanism of BCG is probably a specific anti-BCG cell-mediated immunity 67. This can also 
explain the side effects like fever, sepsis, hepatitis, pneumonitis, arthritis, prostatitis, and uveitis after 
intravesical BCG therapy 68. To date, only 11 cases of ocular inflammations after intravesical BCG 
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	therapy have been published 69- 76.  
 
The first case report was in 1988, about a patient who had an endophthalmitis 5 months following the 
last intravesical BCG application 75. The next publication was in 1994 from Price et al. about a patient 
with acute iritis and arthritis 3 weeks after BCG therapy for the bladder carcinoma 69. The cases with 
ocular inflammation published to date due to intravesical BCG application include 2 cases of 
endophthalmitis 75, 76, 1 case of chorioretinitis 73, 7 cases of uveitis (3 cases of anterior uveitis 69, 72, 46, 1 
case of anterior and posterior uveitis71, 2 panuveitis 74, 77, 1 bilateral uveitis 70), 1 case of autoimmune 
retinopathy 73.  
 
In our study 46 on the in vitro lymphocyte responses in a patient with a bilateral granulomatous iritis 
after intravesical BCG treatment for her bladder carcinoma, we showed elevated cytokine responses to 
all tested retinal antigens and peptides from S-Ag and IRBP as well as to chicken ovalbumin and PPD 
that more frequently showing T-helper (Th1)-type reactivity with secretion of IFN-Υ, IL-6, IL-8 and 
tumor necrosis factor-α (TNF- α) 46. We detected no IL-17 response 46. The blood sample of this patient 
was collected 6 weeks after the onset of her uveitis. There are many researches trying to find the 
immunological mechanism of the uveitis in an animal model. Kaufmann et al.78 have published lately a 
paper about the dynamics of intraocular cytokines during relapsing and monophasic autoimmune 
uveitis in an experimental rat model. According to this study during the monophasic Experimental 
Autoimmune Uveitis (EAU) T-cells co-expressing IFN-Υ and IL-17 increased, and those populations 
were decreased during the primary course of relapsing disease. It could be speculated that in our 
research with the periphery lymphocytes taken from a patient with iritis after the intravesical BCG 
application, due to the late time point of taking the blood sample (6 weeks after the first visit) the initial 
response of IL-17 may be missed.  
 
As a conclusion, mycobacterium tuberculosis can cause uveitis by mycobacterium either invading the 
eye 79 or due to immune response called antigenic mimicry, when T-cells activated by M. tuberculosis 
mistake retinal proteins for antigens from BCG. Systemic infection with M. tuberculosis may also cause 
this inflammation of the eye by a cross-reactive immune response, as observed here after BCG 
therapy, when T cells recognize mycobacterial antigens as well as ocular proteins. This phenomenon, 
called antigenic mimicry, was a presumed cause of uveitis 59, 80, 46. 
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	5.2. Bilateral Acute Iris Transillumination 
Another rare cause of uveitis is a newly described disease called: Bilateral acute iris transillumination 
(BAIT). Up to date there is only one article of 26 patients reported with the similar clinical findings. All 
patients developed bilateral acute iris transillumination associated with pigment dispersion and 
persistent mydriasis 54. Twenty patients were women and 6 were men. The mean patient age at the 
first presentation was 43.2 years. All the patients had bilateral involvement and an acute onset of 
ocular symptoms. Twenty-three patients (88%) reported having acute onset of severe photophobia and 
all patients reported bilateral red eyes. Ten patients (38%) reported also having ocular pain and a 
minority of the patients had blurred vision (27%).  
 
Interestingly, prior to onset of the ocular symptoms, nineteen patients (73%) reported having a flulike 
illness or upper respiratory tract infection. All these patients had been also treated with systemic 
antibiotics, including moxifloxacin in 9 (35%), ampicillin-sulbactam in 2 (8%), amoxicillin-clavulanate in 
2 (8%), and trimethoprim-sulphamethoxazole, cefixime, and penicillin V in one (4%) each. Three 
patients could not recall the name of the antibiotic they had used.  
 
Recently, pigment dispersion and iris transillumination were also described after oral moxifloxacin 
treatment. The first article was published in 2004 81 as a case report of a 77 year-old patient having an 
acute anterior bilateral uveitis and pigmentary dispersion after treatment of a pneumonia with 
moxifloxacin. In 2009, five years later, Wefers Bettink-Remeijer et al. described 5 patients having an 
acute onset of photophobia and pain followed by bilateral diffuse iris transillumination with sphincter 
paralysis 82. Both authors speculated this condition as an ocular adverse effect of moxifloxacin. In the 
case series of BAIT 54 only 35% of the patients reported moxifloxacin intake prior to the ocular 
symptoms. Interestingly a majority of the patients (73%) in this case series reported having flulike 
symptoms, and the authors believed that this condition was triggered by a viral infection.  In spite of 
having so many speculations, the cause of BAIT remains still unknown.  
 
There are also other uveitis entities, which are presumed be caused by a systemic viral infection. Acute 
posterior multifocal placoid pigment epitheliopathy (APMPPE) is characterized by plaque-like lesions at 
the retinal pigment epithelium and causes temporary visual loss. In 1968 83 Gass described the clinical 
and angiographic findings of APMPP in 3 young women. Recently there have been reports associating 
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	it with systemic infection. In 2001 O’ Halloran et al.84 have described 9 cases diagnosed with APMPP 
and 5 patients had a prodromal illness. Many other authors have reported it occurring after a viral 
prodrome 85- 87. In spite of many speculations like a viral cause or APMPP occurring after varicella 
vaccination 88, the real cause of this disease remains unknown.  
 
The initial clinical findings of BAIT were conjunctival hyperemia (12 eyes, 23%), pigment keratic 
precipitates (21 eyes, 40%), circulating pigment in the anterior chamber (45 eyes, 87%), 
transillumination of the iris (52 eyes, 100%), mydriatic pupil with sphicter paralysis (46 eyes, 88%), 
irregular distorted pupil (32 eyes, 62%), and posterior synechia (4 eyes, 8%)(Fig 6). None of those 
patients had inflammatory cells in the anterior chamber at the first presentation or during the follow-
ups. Twenty-one patients (42 eyes) had severe diffuse transillumination of the iris and mydriatic pupil 
with poor or no response to light due to sphincter paralysis. Also an irregular distorted pupil was seen 
in 20 patients (32 eyes). Posterior synechiae was noted only in 3 patients (4 eyes). In ten patients (19 
eyes) pigment dusting on lens was seen.  
 
Figure 6. Case 1: 44-year-old female patient.  
The mydriatic pupils are poorly responsive to light in the right and left eyes. Severe diffuse iris transillumination is evident in the 
right and left eyes on retroillumination. Note the smeared iris pigment on the surface of the lens. The photographs were taken 
without pharmacologic dilation of the pupils. (taken from Tugal-Tutkun I, Onal S, Garip A et. al. Bilateral Acute Iris 
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	Transillumination, Arch Ophthalmol. 2011;129(10):1312-1319) 54 
 
Early rise intraocular pressure (IOP) is a common complication and can be challenging during the 
acute pigment dispersion. Initial IOP higher than 21 mmHg was measured in 8 patients (11 eyes). 
Fourteen patients (54%) had IOP rise during the disease course and 10 received anti-glaucomatous 
medications during the follow-up. Twelve patients needed systemic anti-glaucomatous treatment (7 
acetazolamide, 5 intravenous infusions of Mannitol 20%). In spite of maximum systemic and topical 
treatment 2 patients needed bilateral trabeculectomy combined with mitomycin applications due to the 
high IOP. Both of those patients had 4+ pigment circulating in anterior chamber prior to surgery and 
after the surgery had dense pigment accumulation inside the bleb. 
 
Acute symptoms were relieved rapidly with topical corticosteroid therapy. Seven patients who were 
seen within one week of acute onset of the symptoms were treated with hourly topical corticosteroids. 
The mean duration of topical corticosteroid treatment was 3.5 months (range 1-8 months). In 11 
patients, topical corticosteroid was discontinued with slow tapering and no relapse was seen. Mean 
time from onset of the ocular symptoms to the complete resolution of the pigment dispersion in the 
anterior chamber was 7.3 months (range 1-18 months) in 14 patients.  
 
As known, there are many causes of iris transillumination like pigment dispersion syndrome (PDS) 89, 
herpetic iridocyclitis 90, 91, pseudoexfoliation syndrome 92, Fuchs uveitis syndrome (FUS) 93, 94 and 
recently described entity named bilateral acute depigmentation of the iris (BADI) 95, 96. 
 
Pigment dispersion syndrome (PDS) is the most difficult disease to differentiate from BAIT. PDS is the 
pigmentation of the intraocular structures which is characterized with mid-peripheral iris 
transillumination with spoke-like pattern, iris concavity, pigment deposits on the corneal endothelium-
Krukenberg spindle-, trabecular meshwork, surface of the lens and zonula 89, 97. PDS is mostly seen in 
young men with myopia 89. It is assumed that the friction between the zonula fibers and the peripheral 
iris causes the destruction of the pigment epithelium and this leads to pigment discharge and the 
transillumination of the iris 89, 98. In the case series of BAIT the iris transillumination was diffuse and all 
patients had acute symptoms like photophobia and redness. The patients in PDS are mostly 
asymptomatic however at the time of intraocular pressure rise headaches and blurry vision due to the 
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	corneal oedema are also described 89. In asymmetric cases of PDS, anisocoria can also be seen 89. 
The pathological mechanism and prevalence of pupil irregularity in PDS are still unknown.  
 
Another differential diagnosis of BAIT is the herpetic iridocyclitis. Herpes simplex virus (HSV) and 
varicella zoster virus (VZV) are both members of the Herpesviridae family. As mentioned before, typical 
clinical findings are mutton fat keratic precipitates often in a triangular shape, which is localized at the 
inferior part of the cornea, unilateral iritis or iridicyclitis, sectoral iris atrophy with well-defined margins 
and distorted pupil 99.  
 
Fuchs’ uveitis syndrome is another syndrome, which causes the depigmentation of the iris. Typical 
clinical findings are unilaterality, generalized, fine, stellate keratic precipitates, iris atrophy, low-grade 
anterior uveitis and vitritis 48. Other features are iris nodules (more then 30% of the cases) and the 
smoothening of the stroma at the early stage of the disease. 5-10% of the cases are bilateral. It is 
mostly asymptomatic and the most common complications are subcapsular cataract and glaucoma. A 
chronic rubella infection or CMV infection is assumed to be the cause of Fuchs’ uveitis syndrome 49, 50. 
The case series of BAIT is clinically distinct from Fuchs’ uveitis syndrome with diffuse transillumination 
of the iris, pigment in the anterior chamber without inflammatory cells, bilaterality and no vitreous 
involvement.  
 
Bilateral acute depigmentation of the iris (BADI) is also a recently described new clinical entity and 
characterized by acute pigment dispersion in the anterior chamber, depigmentation of the iris stroma 
and pigment deposition in the anterior chamber angle 100. The patients have bilateral involvement and 
present with photophobia, red eyes and ocular pain at the acute onset of the disease. In contrast to 
BAIT, those patients with BADI do not have pigment deposition on the lens or transillumination of the 
iris as the pigment dispersion is on the anterior stromal layer of the iris. In the case series with BADI 
none of the patients except for one patient had pupil irregularity 100. In BAIT, all patients had diffuse 
transillumination of the iris and pupil irregularity.  
 
 
In conclusion, in those two papers we describe two rare entities of anterior uveitis. In the first paper 
called ‘Uveitis in a patient treated with Bacille-Calmette-Guérin: Possible Antigenic Mimicry of 
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	Mycobacterial and retinal Antigens’, we describe a patient with an anterior uveitis after intravesical 
BCG treatment for her bladder carcinoma and tried to find out the cause of the uveitis. This study has 
shown that potential antigenic mimicry between mycobacterial proteins and retinal autoantigens may 
induce an aggressive immune response that targets the eye.  
 
In the second paper called ‘Bilateral Acute Iris Transillumination’, we describe a rare, new clinical 
entity, which looks like an acute iridocyclitis, but has distinct features not fitting any form of known 
causes of uveitis. There are two possible explanations for the destruction of the iris pigment epithelium 
resulting in transillumination. First theory involves the direct cytopathic effect of a virus on the infected 
iris tissue. The second theory involves a potential antigenic mimicry of (unknown) viral proteins/ 
peptides of an extraocular (systemic) virus infection and proteins of the iris pigment epithelium, 
recognized by cross-reactive CD8+ cytotoxic T cells, which destroy the pigmented cells of the iris. It is 
important to differentiate BAIT from the other causes of uveitis because of the high risk of early severe 
IOP rise, which needs short-term follow-up of the patients in order to avoid visual loss. 
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	6. Summary 
English:  
Anterior uveitis is an inflammation of the iris or/ and the anterior ciliary body of the eye. Besides known 
infectious and non-infectious causes, recently there have been a few publications on the new entities 
or possible causes of AU.  An infectious agent (bacteria or virus) can either invade the eye and cause 
inflammation, however a systemic infection can also cause an inflammation of the eye by a cross-
reactive immune response, as observed after intravesical BCG treatment of bladder carcinoma. This 
mechanism called antigen mimicry could be explained by T-cells activated by M. Tuberculosis (either 
by a systemic infection or by an intravesical application of BCG) mistake retinal proteins for antigens 
from BCG and cause inflammation.  
 
Another recently described entity named bilateral acute iris transillumination (BAIT) is a disease of 
unknown cause. There is only one article of 26 patients published with similar clinical findings. The 
majority of the patients (73%) with BAIT had a flulike illness or upper respiratory tract infection, prior to 
the onset of the ocular symptoms. Therefore, the authors believe that this clinical condition can be 
caused by a viral infection. There are also two reports, which were published in 2004 and 2009, with 
similar clinical findings, but the authors speculated this disease as an adverse affect of moxifloxacin. 
However the real cause of this disease still remains mysterious.  
 
In spite of the rarity of these entities, as clinicians, we should be aware of these new clinical entities in 
order to avoid early visual loss. 
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	7. Zusammenfassung 
Bei der anterioren Uveitis (AU) handelt es sich um eine Entzündung der Iris und/oder des vorderen 
Ziliarkörpers des Auges. Neben infektiösen und nicht-infektiösen Ursachen der AU sind in letzter Zeit 
auch vermehrt Berichte von anterioren Uveitiden durch zuvor nicht bekannte Ursachen veröffentlicht 
worden sowie Entitäten, die denen einer AU ähnlich sind.  
 
Bei einer infektiösen Pathogenese kann es hierbei entweder zu einem direkten Befall des Auges durch 
einen Keim (Bakterium oder Virus) kommen, der in der Folge eine Entzündung verursacht. Auch 
möglich ist darüber hinaus eine zugrunde liegende  systemische Infektion, die durch eine 
Kreuzreaktion zu einer immunologischen Antwort führt und nachfolgend eine Entzündung im Auge 
verursacht, wie sie zum Beispiel nach einer BCG Behandlung bei einem Blasenkarzinom beobachtet 
werden kann. Dieser Mechanismus wird als sogenannte antigene Mimikry bezeichnet. Eine Erklärung 
hierfür beruht auf der These, dass durch M. Tuberculosis (entweder durch eine systemische Infektion 
oder aber auch durch eine intravesikale Anwendung von BCG) eine Aktivierung von T-Zellen 
herbeigeführt wird. Diese T-Zellen erkennen dann im Verlauf retinale Proteine fälschlich als Antigene 
und können so zu einer Entzündung führen. 
 
Einem der AU ähnliches, erst kürzlich beschriebenes Krankheitsbild, ist die sogenannte bilaterale 
akute Iris Transillumination (BAIT), deren Ursache nach wie vor nicht bekannt ist. Hierzu existiert 
zurzeit lediglich eine Veröffentlichung, die insgesamt 26 Patienten mit ähnlichen klinischen Befunden 
einschließt. Der Mehrzahl dieser Patienten (73%) ging den okulären Symptomen im Sinne einer BAIT 
eine grippeähnliche Symptomatik oder eine Infektion des oberen Atmungstraktes voraus. Aus diesem 
Grund schließen die Autoren, dass diese Erkrankung durch eine Virusinfektion verursacht werden 
kann. Auch wenn es bisher nur eine Veröffentlichung zu diesem Krankheitsbild gibt, lassen zwei 
weitere Fallberichte aus den Jahren 2004 und 2009 auf das gleiche Krankheitsbild schließen. In diesen 
wird über Patienten berichtet, die sehr ähnliche klinische Symptome aufwiesen, jedoch bereits unter 
Moxifloxacin Therapie standen, weswegen die Autoren in diesen Fällen von einer Nebenwirkung des 
Antibiotikums ausgingen. Ob es sich auch in diesen Fällen um eine Erkrankung im Sinne einer BAIT 
gehandelt haben könnte, kann jedoch retrospektiv nicht mehr sicher beurteilt werden. 
Trotz der Seltenheit dieser klinischen Manifestationen ist die Kenntnis dieser für Kliniker von 
besonderer Bedeutung, um auch in diesen Fällen eine Sehschärfenminderung zu vermeiden. 
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